REVIEW ARTICLE



Is impaired lung function related to spinal deformities in patients with adolescent idiopathic scoliosis? A systematic review and meta-analysis—SOSORT 2019 award paper

Mandy M. P. Kan¹ · Stefano Negrini^{2,3} · Francesca Di Felice⁴ · Jason P. Y. Cheung⁵ · Sabrina Donzelli⁴ · Fabio Zaina⁴ · Dino Samartzis^{6,7} · Esther T. C. Cheung¹ · Arnold Y. L. Wong¹

Received: 8 August 2022 / Revised: 8 August 2022 / Accepted: 27 August 2022 / Published online: 12 December 2022 © The Author(s) 2022

Abstract

Purpose Some teenagers with adolescent idiopathic scoliosis (AIS) display compromised lung function. However, the evidence regarding the relations between pulmonary impairments and various spinal deformity parameters in these patients remains unclear, which affects clinical management. This systematic review and meta-analysis aimed to summarize the associations between various lung function parameters and radiographic features in teenagers with AIS.

Methods A search of PubMed, Embase, PEDro, SPORTDiscus, CINAHL, Cochrane Library, and PsycINFO (from inception to March 14, 2022) without language restriction. Original studies reporting the associations between lung function and spinal deformity in patients with AIS were selected. Independent reviewers extracted data and evaluated the methodological quality of the included studies according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Pearson correlation and 95% confidence intervals were calculated using random-effects meta-analysis.

Results Twenty-seven studies involving 3162 participants were included. Limited-quality evidence supported that several spinal parameters were significantly related to lung function parameters (e.g., absolute value and percent of the predicted forced vital capacity (FVC; %FVC), forced expiratory volume in one second (FEV₁; %FEV₁), and total lung capacity (TLC; %TLC)) in AIS patients. Specifically, meta-analyses showed that main thoracic Cobb angles in the coronal plane were significantly and negatively related to FVC (r = -0.245), %FVC (r = -0.302), FEV₁ (r = -0.232), %FEV₁ (r = -0.348), FEV₁/FVC ratio (r = -0.166), TLC (r = -0.302), %TLC (r = -0.183), and percent predicted vital capacity (r = -0.272) (p < 0.001). Similarly, thoracic apical vertebral rotation was negatively associated with %FVC (r = -0.215) and %TLC (r = -0.126) (p < 0.05). Conversely, thoracic kyphosis angles were positively related to %FVC (r = 0.180) and %FEV₁ (r = 0.193) (p < 0.05).

Conclusion Larger thoracic Cobb angles, greater apical vertebral rotation angle, or hypokyphosis were significantly associated with greater pulmonary impairments in patients with AIS, although the evidence was limited. From a clinical perspective, the results highlight the importance of minimizing the three-dimensional spinal deformity in preserving lung function in these patients. More research is warranted to confirm these results.

Keywords Pulmonary function \cdot Spinal deformity \cdot Thoracic deformity \cdot Adolescent idiopathic scoliosis \cdot Systematic review \cdot Meta-analysis

Arnold Y. L. Wong arnold.wong@polyu.edu.hk

- ¹ Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China
- ² Department of Biomedical, Surgical and Dental Sciences, University "La Statale", Milan, Italy
- ³ IRCCS Istituto Ortopedico Galeazzi, Milan, Italy

- ⁴ Italian Scientific Spine Institutes (ISICO), Milan, Italy
- ⁵ Department of Orthopaedics and Traumatology, The University of Hong Kong, Hong Kong SAR, China
- ⁶ Department of Orthopedic Surgery, Rush University Medical Center, Chicago, USA
- ⁷ International Spine Research and Innovation Initiative (ISRII), Rush University Medical Center, Chicago, USA

Introduction

Adolescent idiopathic scoliosis (AIS) is a common threedimensional spinal deformity affecting teenagers [1]. Females are 1.4–7.2 times more likely to have AIS than males [2]. While the etiology and risk factors for the development or progression of scoliosis remain inconclusive [3], AIS and/or related treatment may cause back pain, insomnia [4], psychological distress, poor body image [5], and suboptimal quality of life [4].

Patients with AIS are not uncommon to demonstrate compromised pulmonary function [6]. Multiple studies have substantiated the presence of suboptimal pulmonary function (e.g., decreased vital capacity) in these patients [7-9]. While up to two-thirds of AIS patients with large scoliotic curves demonstrate restrictive respiratory abnormalities [10], recent research suggests that suboptimal ventilatory function may occur in patients with mild or moderate AIS [7, 11]. Despite the controversy [12, 13], the suboptimal pulmonary function in these patients may be related to the distortion/restriction of the spine and/or thoracic cage [14], locations of the deformity, reduced chest wall mobility [15], and/or obstructive lung disorders secondary to intrathoracic airway compression [16]. Further, patients' pulmonary function can be compromised by the curve progression [9], and/ or bracing [8, 9, 16, 17]. Conversely, these changes may be reversed by aerobic exercises.

Although a recent systematic review with meta-regression analysis revealed that the pulmonary function in patients with idiopathic scoliosis was inversely related to the curve severity [18], this review was limited by the summary of associations between coronal Cobb angles and various pulmonary parameters among patients of different types of idiopathic scoliosis. Because AIS is a three-dimensional spinal deformity, examining these associations based on coronal Cobb angles alone is incomprehensive [19]. Additionally, findings from a mixed cohort of patients with various idiopathic scoliosis cannot be generalized to patients with AIS. The current systematic review and meta-analysis addressed these limitations and summarized the evidence regarding the associations between various pulmonary functions and spinal parameters in patients with AIS, which may help clinicians identify patients at risk of having pulmonary impairment. Therefore, this review aimed to summarize the evidence regarding the: (1) associations between various pulmonary parameters and the severity of scoliosis in AIS patients; and (2) temporal relations between changes in the spinal curve due to progression/conservative treatments and the corresponding changes in pulmonary function.

Methods

This review protocol was registered with PROSPERO (CRD42016043599) and followed the Preferred Reporting Items of Systematic Reviews and Meta-analysis guidelines [20].

Search strategy

Seven databases: PubMed, Embase, PEDro, SPORTDiscus, CINAHL, Cochrane Library, and PsycINFO were searched for potential articles from inception to March 14, 2022. There were no restrictions on languages, but only English, Chinese, and Italian publications were screened. Search terms included keywords related to pulmonary function, spinal deformity, and AIS. Specifically, the Boolean search strings included ("cardiac*" OR "pulmonary" OR "lung" OR "thoracic" OR "cardiopulmonary") AND ("test*" OR "exam*") AND ("adolescent*" OR "teen*" OR "puberty" OR "youth") AND ("AIS" OR "adolescent idiopathic scoliosis"). The detailed search strategy is included in Supplementary Material eTable 1.

Eligibility criteria

Articles were included had they reported an association between pulmonary function and the severity of spinal curve in patients with AIS aged between 10 and 18 years [21]. Longitudinal, cross-sectional, and case–control studies were eligible. Randomized controlled trials were included if they reported the targeted associations in AIS patients preoperatively, or before and/or after conservative treatments. Studies were excluded had they examined patients with scoliosis other than AIS, cognitive impairment, Marfan syndrome, or pectus deformity.

Screening

Three independent reviewers (MK, JY, and RC) paired up to screen titles and abstracts of all identified citations for eligibility. Studies deemed to be eligible by either reviewer were included for full-text screening. Reviewers repeated the same procedure for full-text screening. If disagreements in inclusion could not be resolved by discussion, a senior reviewer (AW) arbitrated the disagreement. The reference lists of all included articles were screened and forward citation tracing was conducted on Scopus to identify additional articles. The corresponding authors of all included studies were contacted by emails to identify omitted studies, or to seek raw data for our meta-analyses.

Data extraction

Two reviewers (MK and RC) independently extracted data from each included paper. Any disagreements were resolved with the third reviewer (AW). The collected data included: (1) study characteristics (e.g., year of publication, study design); (2) participants' characteristics (e.g., age and gender); (3) absolute values and/or percentage predicted values of pulmonary parameters; (4) spinal/thoracic deformity parameters; and (5) statistical analyses of the associations between (3) and (4). If the included studies conducted subgroup analyses, relevant data were extracted. Missing data was marked as "not reported." A list of definitions of pulmonary and spinal parameters is shown in eTable 2. This includes common terminology such as Lenke and King's classifications of scoliotic curve [23], angle of trunk rotation [22], surface spinal penetration index [24] and endothoracic hump ratio [25].

Risk of bias assessments

Two independent reviewers (RC and AW) assessed the methodological quality of prospective studies using the Quality in Prognostic Studies (QUIPS) [26], cross-sectional studies using Appraisal tool for Cross-Sectional Studies (AXIS) [27], and case–control studies using Newcastle–Ottawa Scale (NOS) [28]. Studies that retrospectively analyzed data or collected data at a single time point were assessed using AXIS. Any disagreements in the assessment results were resolved by consensus.

Data syntheses

Meta-analyses

The primary measure was the associations (e.g., Spearman's/ Pearson coefficients) between various spinal parameters and pulmonary functions in patients with AIS. The correlation coefficients were interpreted as weak, moderate, and strong if their values were 0.3, 0.5, and 0.7, respectively [29]. If three or more clinically homogenous studies investigated the same association, data were pooled for meta-analysis using random-effects model using the Comprehensive Metaanalysis version 3.0 software (Biostat, NJ, USA). Separate meta-analyses were conducted for studies involving multiple regression models. The significance level was set at 0.05. Statistical heterogeneity of the included studies in meta-analyses was graded as low, moderate, and high if the I^2 statistics were $\leq 25\%$, between 26 and 74\%, and $\geq 75\%$, respectively [30]. If meta-analyses were not conducted, the correlations were summarized narratively.

Subgroup analyses

Subgroup analyses were planned to examine the cross-sectional/longitudinal associations between spinal parameters and pulmonary functions based on: (1) genders; (2) severity of the pulmonary impairment; (3) severity of scoliosis; (3) thoracic or lumbar scoliosis; and (4) before and after conservative treatments or curve progression.

Levels of evidence

Levels of evidence were rated as strong, moderate, limited, and very limited based on established criteria (eTable 3) [31, 32].

Results

Database searches yielded 3723 non-duplicated titles and abstracts for screening. Twenty-one out of 278 full-text articles were included. Further, manual searches of reference lists and forward citation of the included articles yielded six additional included articles (Fig. 1).

Study characteristics

Table 1 summarizes characteristics of the 22 included cross-sectional studies [8, 9, 11, 16, 17, 33-49] and five case-control studies [7, 50-53] that involved 3,162 participants. All included studies used spirometry and some also used plethysmography [9, 16, 33, 41, 49, 53] to evaluate lung function. The reported pulmonary function parameters included the absolute values of forced vital capacity (FVC), forced expiratory volume in the first second (FEV₁), FEV_1 / FVC ratio, forced expiratory flow at 25% and 75% of FVC (FEF_{25-75%}), FEF_{25%}, FEF_{50%}, peak expiratory flow (PEF), vital capacity (VC), residual volume (RV), total lung capacity (TLC), RV/TLC ratio, functional residual capacity, etc. Some studies reported these parameters as the percentage of predicted values (e.g., %FVC, %FEV₁, and %TLC). The predicted values were determined according to age-, gender-, and height-matched normative data [54]. Some included studies used equations to estimate patients' "actual height" from the arm span [7, 8, 16, 17, 35–37, 39, 47, 48, 53] or Cobb angles [11, 42, 45] to predict participants' pulmonary functions. Pulmonary functions were considered normal if their measured values exceeded 80% of the predicted values [9, 49].

Spinal parameters were measured by X-rays or computed tomography scans. Five studies used biplanar X-rays with three-dimensional reconstruction of the spine and/or rib cage



Fig. 1 PRISMA flow diagram

[17, 33, 43, 49, 55]. The reported spinal parameters included proximal thoracic Cobb angles [9, 35, 43, 55] main thoracic Cobb angles on anteroposterior radiographs in a standing [7, 8, 16, 17, 29–35, 34–43, 41–49, 53, 55] or supine bending position [39], thoracic kyphosis angles [9, 35, 41, 43, 45], and apical vertebral rotation angles [17, 39, 43, 49, 50, 55] (Table 1). Most included studies used univariate analyses to determine the associations of interest. Nine studies used multiple regression to evaluate such associations [9, 16, 38, 39, 37–44, 51] (Table 1).

Risk of bias assessments

All 22 included cross-sectional studies did not justify their sample sizes, nor report the response rate or non-responders' characteristics [8, 9, 11, 16, 17, 29–35, 33–49, 55] (eTable 4). Five cross-sectional studies [17, 37, 38, 40, 55] did not describe participants' demographics (e.g., gender distribution) [17, 38, 40], while seven studies [11, 34, 37, 39, 46, 48, 49] did not discuss their limitations. Nine included studies did not mention the ethical approval or the informed consent process [9, 11, 34, 33–39, 43, 44, 46]. Similarly, all included case–control studies [7, 46–53] did not describe the non-response rate, while four of them [7, 47–53] did not describe the recruitment process of controls (eTable 5).

Associations between spinal parameters and lung function

Univariate correlations between 43 spinal parameters and 32 pulmonary function parameters were reported (Table 2 and eTable 6). Twenty-seven meta-analyses were conducted to reveal 22 significant correlations. Of them, 20 showed significant but weak correlations. Further, 11 included studies used multivariate analyses to identify independent spinal parameters that predicted pulmonary function [9, 11, 16, 38, 39, 41–44, 51, 53]. Given the numerous investigated correlations, only significant correlations with at least limited-quality evidence were reported and discussed in this review.

No included studies investigated the gender-related correlations between spinal parameters and lung function. No included studies reported the temporal relations between changes in spinal structure and the corresponding changes in pulmonary function in conservatively treated patients with AIS. Although Lin et al. [35] reported that lung function parameters did not significantly differ between AIS patients with and without a history of brace usage, some studies [44, 51] found that compared to "non-brace" patients, those with bracing had poorer lung function. Furthermore, some studies compared patients' lung function based on different Lenke classification types [47, 48], a Cobb angle cutoff [52],

Region/ Country Country 0018 Ara- bia wa Japan 0021	Study design control Prospec- tive cohort (cross- sectional analysis of pre-op data)	No. of par- ticipants (% of female) 73 AIS (76.7%) with Cobb angle of 10° to 20° 34 Healthy controls (85.3%) 45 (91.1%)	Age ± SD (years) 13.4 ± 1.3 14.4 (range 12 to 19) at surgery	Measures X-ray Spirometry Used arm mate height for predicting lung func- tions X-ray Used Cobb angle to estimate cor- rected height in predicting lung func- tions	Coronal/ Sagittal Tx Cobb angles \pm SD $16.4^{\circ} \pm 1.6^{\circ}$ (range 12° to 19°) $53.6^{\circ} \pm 10.1^{\circ}/$ $15.7^{\circ} \pm 10.3^{\circ}$	Type of curve Tx curve (n=67): Right (n=57): Right (n=54) Left $(n=1)$ Troacolumbar curve $(n=6)$: Right $(n=5)$: Left $(n=1)$ Proximal and min Tx curve Lx curve Lx curve Lx curve Lx curve (n=24) Type 2 $(n=12)$ Type 2 $(n=12)$ Type 5 $(n=12)$	Outcome measured FEV, FEV, FEV, FEV, FEV, FEV, FEV, FEV,	The control of the c
S Spain	Case- control	37 (100%) with Cobb angle 20° to 45° Healthy control: 10 (100%)	13.6±1.5 (range 11 to 16) Healthy controls 13.0±0.9	X-ray Raimondi ruler Spirometry	32.8° (range 20° to 45°)	Single Tx curve $(n = 4)$ Thoracolumbar curves $(n = 4)$ Double curves: King II (n = 23); King III $(n = 23)$; King	FFF 80% FEF 25% FEF 50%/ FEF 50%/ FEF 50% AVR AVR FEV 1 FEV 1 FEF 1 50% FEF 1	AVR and FEV ₁ /FVC ($r = -0.461$, $p < 0.05$) No significant difference in FVC and FEV ₁ between AIS patients and healthy controls FVC and FEV ₁ in AIS patients aged <13 years lower than those \geq 13 years ($p = 0.03$)

Table 1 (ct	ontinued)								
Authors	Region/ Country	Study design	No. of par- ticipants (% of female)	Age±SD (years)	Measures	Coronal/ Sagittal Tx Cobb angles±SD	Type of curve	Outcome measured	Findings
Bouloussa et al. 2019 [33]	France	Cross- sectional	54 (83.3%) Tx Cobb angle > 50°	13.8±1.2	X-ray (bipla- nar) Spirometry Plethysmog- raphy	68.7° ± 16.7°/ 20.5° ± 13°	Lenke 1 (n = 44) Lenke 2 (n = 10)	Tx Cobb angle Tx Kyphosis (T4-T12) Rib cage volume SPI Max rib Max rib cage thick- ness Max rib cage width FV/ FV/ TLC TLC SVC	There were significant relations between: T x Cobb angle and FVC (rho = -0.37 , $p = 0.007$), T x Cobb angle and TLC (rho = -0.47 , $p = 0.0001$), T x Cobb angle and SVC (rho = -0.44 , $p = 0.001$); RCV and FVC (rho = 0.77 , $p < 0.0001$). RCV and FEV (FVC (rho = 0.73 , $p = 0.014$), RCV and SVC (rho = 0.73 , $p < 0.0001$). RCV and SVC (rho = 0.78 , $p < 0.0001$). RCV and SVC (rho = 0.78 , $p < 0.0001$); RCV and SVC (rho = 0.78 , $p < 0.0001$); RCV and SVC (rho = 0.26 , $p < 0.001$); Rib cage thickness and FVC (rho = 0.26 , $p < 0.001$); Rib cage thickness and FVC (rho = 0.23 , $p < 0.005$); and Max rib hump and FVC (rho = 0.26 , $p < 0.001$). Rib cage width and FVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and FVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and FVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0.60 , $p < 0.0001$), Max rib cage width and SVC (rho = 0
Daruwalla and Tan, 1985 [46]	Singa- pore	Prospec- tive (cross- sectional analysis of pre-op data)	30 (93.3%)	14.5±1.9 (range 10 to 17)	X-ray Spironeter	56.3° ± 16.6° (range 40°to 100°)/ No report	Tx curves: 2 double curves 26 right Tx curve 6 left Tx curve	Tx Cobb angle %FEV ₁ %FVC	Tx curve was negatively correlated with % FEV $_{\rm I}$ ($p<0.001$) & % FVC ($p<0.005$)
Gitelman et al. 2011 [47]	USA	Longi- tudinal (retro- spective analysis of pre-op data)	49 (93.9%)	14.3 ± 2.4 at surgery	X-ray Spirometry Used arm span to esti- mate height for predicting lung func- tions	56.8°/ 20.9°	Lenke: type 1: (n = 20) type 2: $(n = 8)$ type 3: $(n = 5)$ type 4: $(n = 2)$ type 6: $(n = 6)$	Tx Cobb angle FEV ₁ %FEV ₁ FVC %FVC	Tx Cobb angle and FEV ₁ ($r = -0.42$, $p = 0.003$) Tx Cobb angle and KFV ₁ ($r = -0.42$, $p = 0.014$) Tx Cobb angle and FVC ($r = -0.39$, $p = 0.007$) Tx Cobb angle and %FVC ($r = -0.41$, $p = 0.004$) Patients with major thoracolumbar/Lx curve (Lenke 5) had a better %FVV ₁ ($p = 0.02$) and %FVC ($p = 0.013$) than patients with a double Tx curve (Lenke 2) Patients with major thoracolumbar/Lx curve (Lenke 5) had a better %FVC ($p = 0.029$) than patients with a double major curve (Lenke 3)
Huh et al. 2015 [34]	South Korea	Cross- sectional (retro- spective review of medical records)	81 (83.3%)	14.8±2.2	X-ray Spirometry	53.8° ± 15.1°/ No report L.x curve: 53.4° ± 15.1°	Tx curve and Lx curve Tx-dominant (n = 72) Lx-dominant (n = 9)	Tx Cobb angle Lx Cobb angle %FEV1 %FEV1 %FEV1	Tx Cobb angle and %FVC ($r = -0.331$, $p = 0.004$) Tx Cobb angle and %FEV ($r = -0.331$, $p = 0.001$) Tx Cobb angle and %FEV ($r = -0.381$, $p = 0.001$) Tx Cobb angle and %FEV ($r = -0.162$, $p > 0.05$) Lx Cobb angle and %FEV ($r = -0.142$, $p > 0.05$) Lx Cobb angle and %FEV ($r = -0.14$, $p > 0.05$) Lx Cobb angle and %FEV ($r = -0.015$, $p > 0.05$)
llharre- borde et al. 2013 [17]	France	Cross- sectional	54 (not reported) Group 1: Cobb angle> 65° (n=22) Group 2: Cobb angle 40° to 65° $(n=32)$	Group 1: 15.1±1.5 Group 2: 14.6±1.2	X-ray (bipla- nar) Spirometry Used arm span to esti- mate bright for predicting lung func- tions	Group I: 73.8° ± 9°/ 17.8° ± 11° 670up 2: 49.2° ± 8°/ 16.3° ± 12°	Tx curve	Tx Cobb angle, Ttx (T4 to T12), AVR Tx volume, Volume SPI, SFVC %FEV , %TLC	Tx volume and %FVC ($r=0.82$, $p<0.0001$) Tx volume and %FEV ₁ ($r=0.76$, $p<0.0001$) Tx volume and %FEV ₁ ($r=0.3$, $p<0.0001$) TK and %FVC ($r=0.4$, $p<0.0001$) TK and % FEV ₁ ($r=0.37$, $p<0.0001$) No correlation was found between pulmonary function tests and Cobb angle or AVR or SPI ($p>0.05$) %FVC and % FEV ₁ were significantly lower in %FVC and % FEV ₁ were significantly lower in the hypokyphotic patients ($<20^{\circ}$) than in the other patients ($p=0.04$ and $p=0.03$, respectively) Volume SPI was significantly greater in the 26 patients with obstructive syndrome (i.e., <80% of %FEV ₁) than in the other 28 patients ($p=0.01$)

				G
	Findings	Tx Cobb angle and %FVC ($r = -0.18$, $p = 0.04$) Tx Cobb angle and the %FEV ₁ ($r = -0.26$, $p = 0.005$) Number of involved vertebras in the major curve and %FVC ($r = -0.27$, $p = 0.003$) Number of involved vertebras in the major curve and %FEV1 ($r = -0.23$, $p = 0.02$) Patients with a thoracolumbar/Lx curve (Lenke 5) had a significantly larger FEV ₁ ($p = 0.045$) than those with a main Tx curve (Lenke 1)	Tx Cobb angle and FVC $(r=0.096, p=0.25)$ Tx Cobb angle and %FVC $(r=0.045, p=0.60)$ Tx Cobb angle and FEV ₁ $(r=0.038, p=0.66)$ Tx Cobb angle and %FEV ₁ $(r=0.004, p=0.96)$	There were significant relationships between: Proximal Tx curve and %FEV ₁ ($r = -0.324$, $p < 0.001$) Main Tx curve and %FEV ₁ ($r = -0.374$, $p < 0.001$); Main Tx curve and %FVC ($r = -0.283$, $p < 0.001$) Tx kyphosis and %FVC ($r = 0.257$, $p < 0.001$); Tx kyphosis and %TV ($r = 0.265$, $p < 0.001$); There were no significant differences ($p = 0.34 - 0.92$) in any lung function parameters betwe patient with ($n = 51$) and without ($n = 117$) history of brace usage
	Outcome measured	Tx Cobb angle Number of vertebrae involved in major curve %FEV1 %FEV1	Tx Cobb angle FVC %FV FEV ₁ %FEV ₁	Proximal Tx curve (T2 to T5) Main Tx curve (T6 to T11) Tx kyphosis (T5 to T12) %FEV1 %FVC FEV1 FEV1FVC %PEF
	Type of curve	Tx curve Lenke: type 1: (n=63) type 2: $(n=18)$ type 3: $(n=7)$ type 4: (n=15) type 5: $(n=15)$ type 6: $(n=11)$	Tx curve Lenke: type 1: (n = 84) type 2: $(n = 25)$ type 3: $(n = 26)$ type 4: $(n = 4)$	Proximal Tx curve Main Tx curve Thoracolum- bar/Lx curve (apex located in and below T12)
	Coronal/ Sagittal Tx Cobb angles±SD	56°/ 16°	$60^{\circ} \pm 11.7^{\circ}$ (range 40° to 91°)/ $21^{\circ} \pm 13.5^{\circ}$ (range 10° to (1°)	Proximal: 28.5° (range 5° to 74°) Main Tx curve: 46.5° (range 14° to 97°) Thoracolum- bar/ Lx curve: 13° to 90°)
	Measures	X-ray Spirometry Used arm span to esti- mate height for predicting lung func- tions	X-ray Spirometry Used arm span to esti- mate height for predicting lung func- tions	X-ray (stand- ing and side- bending) Spirometer Gas analyzer Used arm span to esti- mate height for predicting lung func- tions
	Age±SD (years)	14.4±1.9 (range 10.9 to 18)	14.6±2.2	Female: 14.2±1.7 Male: 15.4±1.6
	No. of par- ticipants (% of female)	118 (93.2%)	139 (82.0%) Lenke type 1–4	168 (85.1%)
	Study design	Prospec- tive (cross- sectional analysis of pre-op data)	Prospec- tive (cross- sectional analysis of pre-op data)	Cross- sectional
	Region/ Country	USA	USA	China
	Authors	Kim et al. 2005 [48]	Kim et al. 2007 [8]	Lin et al. 2022 [35]

🙆 Springer

Table 1 (continued)

	Findings	The main Tx Cobb angle was significantly correlated with VC ($r = -0.277$, $p < 0.05$), FVC ($r = -0.307$, $p < 0.05$), and FEV ($r = -0.277$, $p < 0.05$) The cephalic Tx apical vertebra rotation was significantly correlated with VC ($r = -0.331$, $p < 0.05$), FVC ($r = -0.336$, $p < 0.05$), and FVV ($r = -0.336$, $p < 0.05$) The main Tx apical vertebra rotation was significantly correlated with VC ($r = -0.254$, $p < 0.05$) FVC ($r = -0.236$, $p < 0.05$), and FEV ($r = -0.308$, $p < 0.05$) and FVC ($r = 0.236$, $p < 0.05$) and FVC ($r = -0.236$, $p < 0.05$), and FVC ($r = -0.236$, $p < 0.05$), and FVC ($r = -0.236$, $p < 0.05$), and FVC ($r = -0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$) and FVC ($r = 0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$) and FVC ($r = 0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$). and FVC ($r = 0.236$, $p < 0.05$). FVC ($r = 0.236$, $p < 0.05$). FVC ($r = 0.236$, $p < 0.001$), FVC ($r = 0.732$, $p < 0.001$), FVC ($r = 0.732$, $p < 0.001$), FVC ($r = 0.732$, $p < 0.001$), FVC ($r = 0.236$, $p < 0.01$), FVC ($r = 0.736$, $p < 0.001$), FVC ($r = 0.236$, $p < 0.01$), FVC ($r = 0.736$, $p < 0.001$), FVC ($r = 0.236$, $p < 0.01$), FVC ($r = 0.732$, $p < 0.000$), FVC ($r = 0.326$, $p < 0.01$), and FEV ($r = 0.232$, $p < 0.001$), FVC ($r = 0.732$, $p < 0.001$), FVC ($r = 0.232$, $p < 0.001$), FVC ($r = 0.233$, $p < 0.001$), FVC ($r = 0.231$, $p < 0.001$), FVC ($r = 0.332$, $p < 0.001$), FVC ($r = 0.332$, $p < 0.001$), FVC ($r = 0.332$, $p < 0.001$), FVC ($r = 0.334$, $p < 0.001$), FVC ($r = 0.334$, $p < 0.001$), FVC ($r = 0.333$, $p < 0.01$), FVC ($r = 0.332$, $p < 0.01$), FVC ($r = 0.333$, $p < 0.01$), FVC ($r = 0.331$, $p < 0.01$), FVC ($r = 0.332$, $p < 0.01$), FVC ($r = 0.332$, $p < 0.01$), FVC ($r = 0.332$, $p < 0.01$), FVC ($r = 0.333$, $p < 0.01$), FVC ($r = 0.333$, $p < 0.01$), FVC ($r = 0.333$, $p < 0.01$), FVC ($r = 0.333$, $p < 0.01$), FVC ($r = 0.33$
	Outcome measured	Cephalic Tx Cobb angle Cobb angle Cephalic Tx AVR AVR AVR Tx kyphosis (T1 to T12) Lx lordosis (T1 to T12) Lx lordosis (T1 to T12) Lx lordosis (L1 to S1) Max. rib cage thick- ness; Max. rib cage width; Tx index; Rib hump; Rib hump; Rib hump; Rib hump; Rib cage volume SPI; Surface SPI at apex; Endotho- racio at mp
	Type of curve	Tx curve Lx curve
	Coronal/ Sagittal Tx Cobb angles±SD	50.8° ± 10.5°/ 22.2° ± 10.4°
	Measures	Biplanar X-ray Spirometry Used arm span to esti- mate height for predicting tions tions
	Age±SD (years)	14.4 (range 11 to 17)
	No. of par- ticipants (% of female)	67 (88.1%) with Lenke type 1 or 2
	Study design	Cross- sectional
ontinued)	Region/ Country	Japan
Table 1 (cc	Authors	Machino et al. 2021 [36]

sternum angle at apex; Rib-vertebral angle difference; differenc

apex; Vertebra-

	ndings	34% patients (= 68/176) had obstructive lung disease, i.e., FEV,/FVC < 95% CI of the predicted value value 18% patients (= 31/175) had restrictive lung disease, i.e., TLC < 95% CI of predicted value TX Cobb angle & %FFV ($r = -0.131$, $p = 0.030$) TX Cobb angle & %FFV ($r = -0.131$, $p = 0.030$) TX Cobb angle & %FFV ($r = -0.175$, $p < 0.05$) TX Cobb angle & %FFV ($r = -0.175$, $p < 0.05$) TX Cobb angle & %FFV ($r = -0.175$, $p < 0.05$) TX Cobb angle & %FFV ($r = -0.128$, $p = 0.030$) TX Cobb angle & %FFV ($r = -0.128$, $p < 0.001$) TX kyphosis angle & %FFV ($r = -0.128$, $p < 0.001$) TX kyphosis angle & %FFV ($r = -0.128$, $p < 0.001$) TX kyphosis angle & %FFV ($r = -0.137$, $p < 0.05$) TX kyphosis angle & %FFV ($r = -0.137$, $p = 0.036$) TX kyphosis angle & %FFV ($r = -0.137$, $p = 0.036$) TX kyphosis angle & %FFV ($r = -0.070$, $p = 0.368$) TX kyphosis angle & %FFV ($r = -0.070$, $p = 0.056$) No. of Tx vertebrae in a curve & %FFV ($r = -0.017$), $p = 0.055$ No. of Tx vertebrae in a curve & %FFV ($r = -0.013$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.013$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.013$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.013$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.013$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.033$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.033$, $p = 0.055$) No. of Tx vertebrae in a curve & %FFV ($r = -0.033$, $p = 0.050$) No. of Tx vertebrae in a curve & %FFV ($r = -0.033$, $p = 0.576$) Multiple regression models . (1) Increased Tx Cobb angle were independent predictors for lower FEV_1 ($r^2 = 0.061$, $p < 0.005$), π LC ($r^2 = 0.061$, $p < 0.05$), and %FRC ($r^2 = 0.061$, $p < 0.05$), and %FRC ($r^2 = 0.061$, $p < 0.05$). $p < 0.001$, $\%$ FFV ($r^2 = 0.052$, $p < 0.05$), and %FRC ($r^2 = 0.061$, $p < 0.05$), and %FRC ($r^2 = 0.061$, $p < 0.05$), and %FRC ($r^2 = 0.061$, $p < 0.05$). $p < 0.05$) models were independent predictors for lower $\%$ FVC ($r^$	No significant relation between main Tx Cobb angle and % VC ($r = -0.161$, $p > 0.1$) No report of correlation between main Tx Cobb angle and other pulmonary function 4 out of 51 patients (7.3%) with AIS had moderately or severely affected lung function (e.g., %TLC or %FEV1 < 60% of predicted value) %TLC or %FEV1 < 60% of predicted value) TX kyphosis (220° ; $n = 21$) (0.5 > $p > 0.1$)
	Outcome F measured	Tx Cobb angle Tx kyphosis angle No. of vertebrae within spinal curve %FEVC %FEV FEV FEV FEV %FEV FEV %FEV FEV %FEV FVC %FEV FVC %FEV	Tx Cobb angle Kyphosis %TLC %VC %RV
	Type of curve	TX curve	Main Tx curve
	Coronal/ agittal Tx Cobb ngles±SD	27.6° ±11.4° 27.6° ±14.4°	52° (range 20° to 93°)/ No report
	Measures C S a	X-ray Spirometry Plethysmog- Used arm span to esti- mate height lung func- tions	X-ray Spirometry Used arm span to esti- mate height for predicting lung func- tions
	Age±SD (years)	13.2±2.1	14.3
	No. of par- icipants (% of `emale)	vith Cobb angle ≥ 40°	51 (80.3%) Other were infantile (n = 16) and congenital (n = 25) scoliosis
	Study I design t f	Cross sectional (retro- spective analysis of preop- records) records)	Cross- sectional (Retro- spective medical reports)
ntinued)	Region/ Country	NSA	United King- dom
Table 1 (cor	Authors	McPhail et al. 2015 [16]	Muithead and Con- ner, 1985 [37]

Table 1 (co	ontinued)								
Authors	Region/ Country	Study design	No. of par- ticipants (% of female)	Age±SD (years)	Measures	Coronal/ Sagittal Tx Cobb angles±SD	Type of curve	Outcome measured	Findings
Newton et al. 2005 [9]	USA	Cross-sectional	631 (84.3%)	Female: 14.5±2.1 Male: 15.7±2.1	X-ray Spirometry Plethysmog- raphy	52° $\pm 14^{\circ}$ (range 2° to 110°)/ 24° $\pm 13^{\circ}$ (range -10° to 64°) Cephalad Tx curve: 26° $\pm 11^{\circ}$ (range -0° to 83°) 17× curve: 37° $\pm 13^{\circ}$ (range 8° to 93°)	Lenke type 1 (n = 394) Lenke 2 (n = 92) Lenke 4 (n = 16) Lenke 5 (n = 16) Lenke 6 (n = 79) Lenke 6 (n = 20)	Cephalad Tx Cobb angle Cephalad Tx curve flexibility Main Tx Cobb angle Main Tx Cobb angle Lx curve flexibility Tx apex level Number of vertebrae within the main Tx apex level Number of vertebrae within the main Tx apex level Number of vertebrae within the main Tx from plumb line at C7 Tx apex level Number of vertebrae within the main Tx curve flexel Number of vertebrae within the main Tx curve flexel Number of vertebrae within the main Tx curve flexel Number of vertebrae within the main Tx curve flexel Number of vertebrae within the main Tx friphosis (T2T12) Lx lordosis %FFV %TLC	Caphalad TX Cobb angle was significantly related to %FVC ($r = -0.202$, $p < 0.002$), %FEV ($r = -0.21$, $p < 0.002$), and %TLC ($r = -0.13$, $p < 0.002$), with r ($r = -0.13$, $p < 0.002$), with r ($r = -0.13$, $p < 0.002$), with r ($r = -0.13$, $p < 0.002$), with r ($r = -0.13$, $p < 0.002$), with $r < r > 0.002$, r ($r > 0.002$), r ($r > 0.013$, r) $r < 0.002$), r ($r > 0.013$, r) $r < 0.002$), r ($r > 0.013$, r) $r < 0.002$), r ($r > 0.013$, r) $r < 0.002$), r ($r > 0.013$, r) r ($r = -0.133$, $p < 0.002$), r ($r > 0.002$), r ($r > 0.013$, r ($r > 0.002$), r ($r > 0.013$, r ($r > 0.002$), r ($r > 0.013$, r), r ($r = -0.143$, $p < 0.002$), r ($r > 0.002$), r ($r >$

Table 1 (cc	ontinued)								
Authors	Region/ Country	Study design	No. of par- ticipants (% of female)	Age±SD (years)	Measures	Coronal/ Sagittal Tx Cobb angles±SD	Type of curve	Outcome measured	Findings
Pietton et al. 2022 [49]	France	Prospec- tive sectional analysis of pre-op data)	45 (84.4%)	14.7 (range 12 to 17) at surgery	X-ray (bipla- nar) Spirometer Plethysmog- raphy	68.2° ± 17 (trange 47° to 1.28°)/ 20.8°	Tx curve Lx curve Lenke: Type 1 $(n \equiv 12)$ $(n \equiv 12)$	Main Tx Cobb angle Tx kyphosis (T4 to T12) Lx lordosis (L1 to S1) AVR Max rib hump Rib cage Max rib cage medial-lat- eral diameter (width) Max rib cage anter- oposterior depth) Hypokypho- sis index FVC SVC FVC FV/FVC	There were significant relationships between: Tx Cobb angle and TLC ($hio = -0.38$, $p = 0.017$) Tx Cobb angle and FVC ($hio = -0.38$, $p = 0.012$) ANR and FVC ($hio = 0.34$, $p = 0.004$) ANR and SVC ($hio = 0.78$, $p < 0.001$) Rib cage volume and FTC ($hio = 0.78$, $p < 0.001$) Rib cage volume and FVC ($hio = 0.78$, $p < 0.001$) Rib cage volume and FVC ($hio = 0.78$, $p < 0.001$) Rib cage volume and FVC ($hio = 0.78$, $p < 0.001$) Rib cage volume and FVC ($hio = 0.78$, $p < 0.001$) Rib cage volume and FVC ($hio = 0.78$, $p < 0.001$) Rib cage vidth and FUC ($hio = 0.74$, $p = 0.003$) Rib cage vidth and FUC ($hio = 0.53$, $p = 0.001$) Rib cage vidth and FUC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage depth and FVC ($hio = 0.53$, $p = 0.001$) Rib cage volumes index and FVC ($hio = 0.34$, $p = 0.006$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.006$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) As polythosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC ($hio = 0.34$, $p = 0.005$) Hypokyphosis index and FVC (
Ran et al. 2016 [5 1]	China	Case- control study	237 (81.9%) 60 AIS brace group; 177 AIS non- brace Apex at T5 (n = 142); apex (n = 142); apex (n = 95)	Brace: 13.7±1.5 Non- brace: 13.4±1.5	X-ray Spirometry	Brace: $53.7^{\circ} \pm 13^{\circ}/$ $22.2^{\circ} \pm 14.5^{\circ}$ $100-brace:53.4^{\circ} \pm 12.7^{\circ}/23.4^{\circ} \pm 15^{\circ}$	Main Tx curve Thoracolum- bar/lumbar curve	Tx Cobb angle Tx Kyphosis angle (T5 to T12) FVC FEV, FEV, %FEV,	Unclear whether the pulmonary function test was performed while wearing a brace Brace group had significantly smaller %FVC, FEV1, and %FEV1 ($p < 0.05$) than non-brace con- trols for those with main Tx curves (not for those with primary thoracolumbar/lumbar curve) Multiple regression models: A greater TX kyphosis was related to better %FVC in brace patients A greater TX kyphosis was afted to better %FVC in brace patients A greater TX kyphosis angle and shorter brace treatment duration were related to better %FV ₁ Independent variables: Age at operation, height, coronal Cobb angle of main curve, number of involved vertebrae, sagittal Cobb angle of thoracic curve, brace treatment time per day, and brace treatment duration
Saraiva et al. 2017 [52]	Brazil	Case- control	AIS: 46 (100%) C obb angles $+5^{\circ}$ $(n = 17); < 45^{\circ}$ (n = 29) Healthy control: 20 (100%)	14±2 (range 10 to 18)	X-ray Spirometry Gas analyzer	Cobb angle >45° group: Cephalic Cobb angle: $26.0^{\circ} \pm 8.0^{\circ}$; m° to 59° ; $Lx: 31^{\circ} (30^{\circ}$ to 39°); $Lx: 31^{\circ} (30^{\circ}$ to 39°) cobb angle <45° group: Cephalic $18.0^{\circ} \pm 5.0^{\circ}$; $Lx: 30^{\circ} (20^{\circ}$ to 36°); $Lx: 30^{\circ} (20^{\circ}$ to 36°); $Lx: 30^{\circ} (20^{\circ}$ to 36°);	Tx and Lx curves	Cephalic Tx Cobb angle; Main Tx Cobb angle; Lx Cobb angle FEV ₁ %FEV ₁ FVC %FVC FEV ₁ FVC FRC FRC	Main Tx Cobb angle and FVC ($r = -0.506$; $p = 0.004$) Main Tx Cobb angle and FFV ($r = -0.462$; $p = 0.010$) AIS Cobb angle >45° group had significantly smaller %FVC ($p < 0.001$) and %FEV ₁ ($p < 0.001$) than those with Cobb angle <45°

	Findings	Tx Cobbs angle and %FVC ($r = -0.466$, $p \sim (0.05)$ The %FVC of patients with moderate curve were significantly lower than normal controls ($p < 0.001$) The were no differences in lung parameters between patients with mild curve and normal There were no differences in lung parameters between patients with mild curve and normal controls ($p > 0.05$) A stepwise multiple regression showed that 61% of variance in %FVC was explained by arm span, age, and Tx Cobb angle (no results were shown) Impairment of pulmonary function was noted in mild-to-moderate AIS patients. Decreased lung volumes were related to the degree of thoracic deformity rather than to the impaired respiratory muscle strength	%VC was significantly related to: Tx Cobb angle $(r = -0.271, p = 0.004)$, Tx kyphosis $(r = 0.056, p = 0.061)$. Ta kyphosis $(r = 0.056, p = 0.061)$. Sagittal diameter (at T5 to T12) $(r = ranging from 0.29)$ to 0.455, $p < 0.007$) Signital diameter (at T5 to T12) $(r = ranging from 0.238 to 0.329, p < 0.007)No correlation between spinal parameters and other pulmonary function parameters (p > 0.05)Independent predictors for %VC in two multivariate regression models:1) total lung area and Raga at T8 (r^2 = 0.301, p < 0.0001)%VC was used as the dependent variable while lateral spinal curvature and thoracic cage deformity (at each vertebral level from T3 to T12) variables were used as independent variables$	Tx Cobb angle and %FVC ($r = -0.23$, $p = 0.01$) Tx kyphosis angle and %FVC ($r = -0.23$, $p = 0.01$) BM and %FVC ($r = 0.37$, $p < 0.01$) BM and %FVC ($r = 0.37$, $p < 0.01$) Tx kyphosis angle and %FVC ($R^2 = 0.26$) The coefficients of determination for: Tx Cobb angle = 0.33 (95% CI: -0.76 to -0.29); Tx kyphosis = 0.31 (95% CI: 0.16, 0.47); and BMI = 1.04 (95% CI 0.52, 1.55) More obesolverweight (BMI ≥ 25) had significantly greater kyphosis angle ($p < 0.05$) and FVC ($P < 0.01$) than those with BMI < 25 Linear regression analysis used FVC as the primary outcome and BMI, TK, and Cobb angle as the independent variables
	Outcome I measured	Main Tx Cobb angle %FVC %FVC	Tx Cobb angle (T1—T12) Hump sum RAsag at T1 to T12 Sagittal diameter of the thoracic cage (at T3 to T12) Kypho- sis-lordosis index (at T3 to T12) FVC, FEV, FEV, FEV, FEV, FEV, FEV, FEV, FEV,	Tx Cobb angle Tx kyphosis (T2 to T12) %FVC BMI
	Type of curve	Tx curve	Right Tx curve King's clas- sification: Type I (n = 12) Type II (n = 12) Type V (n = 12) Type V (n = 12) Apex at T3 to T10 $(n = 19)$ Apex at T3 to T10 $(n = 90)$	Tx curve
	Coronal/ sagittal Tx Cobb ingles±SD	Moderate: 49° ± 8° (range 35° to 60°) Mid: 21° ± 8° (range 10° to 35°)	37.7° ± 15.6° (range 16° to 28.2°) (range 0° to 50°)	59°/ 35°
	Measures 6	X-ray Spirometry Body Dethysmog- raphy Used arm span to esti- mate height for predicting lung func- tions	CT scan Moiré topog- Spirometry with Helium dilution (Cobb angle) to estimate height for predicting lung func- tions	Х-гау Spiromery
	Age±SD (years)	Moderate: 14.0 ± 1.7 Mild: 13.6 ± 1.7 Normal controls: 14.8 ± 1.6	14.2 ± 1.8	14 (SD not reported)
	No. of par- ticipants (% of female)	12 moderate curve (35° – 60°) (100%) 12 mild curve (<35°) (100%) 38 Normal controls (100%)	109 (91.7%)	142 with Cobb angle > 50° (No informa- tion on gender)
	Study design	Case- control	Cross- sectional fretro- spective of medical records)	Cross- sectional (Retro- spective analyses of preop- eration data)
ntinued)	Region/ Country	Can- ada	Japan	USA
Table 1 (co	Authors	Szeinberg et al. 1988 [53]	Takahashi et al. 2007 [11]	Tung et al. 2018 [38]

Authors	Region/ Country	Study design	No. of par- ticipants (% of female)	Age±SD (years)	Measures	Coronal/ Sagittal Tx Cobb angles±SD	Type of curve	Outcome measured	Findings
Upadhyay et al. 1995 [39]	H ong K ong	cross-sectional	- 70 (91.4%)	- 13.8±2.1 (range 10 to 18)	X-ray (standing bending to the right) Spirometry with Helium Used arm span to esti- mate height for predicting thons tions	$-59.0^{\circ} \pm 14.1^{\circ}$ (range 35° to $100^{\circ}/$ $-24.7^{\circ} \pm 15.1^{\circ}$ $-(range -7^{\circ}$ to 55°) to 55°)	Right Tx curve: Apex at T8 to T10 $(n = 60)$ Apex at T7 or T11 $(n = 10)$	Tx Cobb angle Curve flex- ibility AVR flex- Kyphosis (T3 – T12) Maximum sternoverte- mation atteropos- terior width attance/ anteropos- terior width attance/ distance/ anteropos- terior width attance/ anteropos- terior width attance/ anteropos- terior width ratio bral angle asymmetry (standing) Rib-verte- bral angle asymmetry (standing) Rib-verte- bral angle asymmetry (standing) Rib-verte- bral angle asymmetry (standing) Rib-verte- bral angle asymmetry (standing) Changes in metry from standing FFV, %CVC FEV, VC, %VC FEV, VC, %CVC FEV, VC, %CVC FEV, VC, %TLC FEP, 23-75% DLCO, %	There were significant relationships between the following measurements: Ts Cobb angle and %FVC ($r = -0.303$, $p = 0.001$), Ts Cobb angle and %FVC ($r = -0.302$, $p = 0.003$), Ts Cobb angle and %FVC ($r = -0.232$, $p = 0.003$, MR and %FVC ($r = -0.233$, $p = 0.003$), MR theshility and %FVC ($r = -0.233$, $p = 0.003$), MR flexibility and %FVC ($r = -0.233$, $p = 0.003$), Sphoiss and FFUC ($r = -0.234$, $p = 0.003$), Sphoiss and FFUC ($r = -0.234$, $p = 0.036$), Sphoiss and FFUC ($r = -0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.036$), Sphoiss and FFUC ($r = 0.234$, $p = 0.037$), Maximum serrowertebral distance and FFUC ($r = 0.260$, $p = 0.032$), Maximum serrowertebral distance and FFUC ($r = -0.260$, $p = 0.032$), Maximum serrowertebral distance and FFUC ($r = -0.260$, $p = 0.032$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.037$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.047$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.047$), Rib-wertebral angle asymmetry (supine bending) and %FVC ($r = -0.236$, $p = 0.047$)

Table 1 (continued)

able 1 (cc uthors	Region/	Study	No. of par-	Age±SD	Measures	Coronal/	Type of curve	Outcome	Findings
	Country	design	ticipants (% of female)	(years)		Sagittal Tx Cobb angles±SD		measured	
/illamor 4 al. 2019 40]	USA	Cross-sectional	91 (unknown) Tx Cobb angle > 20° Non-brace (n = 46) Brace (n = 14) Planning surgery (n = 31)	14 (range 11 to 17)	X-ray Scotiometer Spirometry	39.5° (range 20° to 88°)	Tx curve	Tx Cobb angle ATR %FEV ₁ FEV ₁ /FVC FVC, %FVC MVV, %MVV	Tx Cobb angle and %FEV ₁ ($r = -0.35$, $p = 0.02$) Tx Cobb angle and FVC ($r = -0.37$, $p = 0.01$) Tx Cobb angle and %FVC ($r = -0.32$, $p = 0.04$) Tx Cobb angle and %FVC ($r = -0.24$, $p = 0.03$) TX Cobb angle and %MVV ($r = -0.24$, $p = 0.03$) ATR and FVC ($r = -0.16$, $p = 0.33$) ATR and %FVC ($r = -0.24$, $p = 0.13$) ATR and %FVC ($r = -0.14$, $p = 0.06$) ATR and %MVV ($r = -0.14$, $p = 0.22$)
Vang et al. 019 [41]	China	Cross- sectional (Retro- spective analyses of preop- erative data)	72 (76.4%) AIS with right main Tx Cobb angles ≥ 45°	Male: 14.7±0.6 Female: 14.9±0.4	X-ray (standing and supine bending) Plethysmog- raphy	67.5° ±17.6°/ 29.3° ±18.9°	Tx curve Lenke: Type 1 (n = 41); Type 2 (n = 14); Type 3 (n = 12); Type 6 (n = 12); Apex at T7 (n = 11); Apex at T8 (n = 11); Apex at T8 (n = 11); Apex at T9 (n = 31); Apex at T10 (n = 6); Apex at T10 (n = 7); Apex at T10 (n = 7); Appx at T10 (n =	Tx Cobb angle TK (T5-T12) Apical vertebral body-to-rib Main Tx AVT Main Tx Main Tx Mai	Tx Cobb angle and %FEV $(r = -0.812, p < 0.001)$ Tx Cobb angle and %FVC $(r = -0.805, p < 0.001)$ TK angle and %FVC $(r = -0.248, p = 0.036)$ TK angle and %FVC $(r = -0.172, p = 0.147)$ Apical vertebral body-or-rib ratio and %FVL $(r = -0.732, p < 0.001)$ Apical vertebral body-or-rib ratio and %FVL $(r = -0.732, p < 0.001)$ Apical vertebral body-or-rib ratio and %FVL $(r = -0.732, p < 0.001)$ Apical vertebral KEV_1 $(r = -0.670, p < 0.001)$ AVT and %FFV $(r = -0.619, p < 0.001)$ AVT and %FFV $(r = -0.532, p = 0.048)$ Curve flexibility index and %FFV $(r = 0.233, p = 0.048)$ Curve flexibility index and %FFV $(r = 0.237, p = 0.01)$ Rib hump and %FFV $(r = -0.725, p < 0.001)$ Rib hump and %FFV $(r = -0.725, p < 0.001)$ Rib hump and %FFV $(r = 0.237, p = 0.022)$ Tx depth and %FFV $(r = 0.227, p = 0.022)$ Tx depth and %FFV $(r = 0.223, p < 0.001)$ Rib hump and %FFV $(r = 0.232, p < 0.001)$ Rib hump and %FFV $(r = 0.232, p < 0.001)$ Rib hump and %FFV $(r = 0.232, p < 0.001)$ Rib hump and %FFV $(r = 0.232, p < 0.001)$ Rib hump and %FFV $(r = 0.232, p < 0.002)$ Tx depth and %FFV $(r = 0.232, p < 0.022)$ Multiple linear regression Tx Cobb angle $(R^2 = 0.648)$, apical vertebral body-to-rib ratio $(R^2 = 0.536)$, AVT $(R^2 = 0.336)$, and rib hump $(R^2 = 0.542)$ vere significant predictors of %FFV $(r > 0.05)$ Tx Cobb angle $(R^2 = 0.648)$, apical vertebral body-to-rib ratio $(R^2 - 0.648)$, apical vertebral body-to-rib ratio, RT, and rib hump $(R^2 = 0.522)$ were significant predictors of %FFV $(r = 0.036)$ Tx Cobb angle $(R^2 = 0.648)$, apical vertebral body-to-rib ratio $(R^2 = 0.548)$, apical vertebral body-to-rib ratio, RT, and rib hump $(r < 0.001)$ Patients with severe lung impairment $(\%FVC < 80\%$ and $\%FFV_1 = 6.058)$. AVT, and rib hump than those with mild-to-moderate impairment $(\%FVC < 80\%$ and $\%FVC_1 = 6.048)$. AVT, and rib hump than those with mild-to-moderate impairment $(\%FVC < 80\%$ and $\%FVC_1 = 6.048)$. AVT, RT, RH and HTAVR-R
Ku et al. 2015 [42]	China	Cross- sectional	120 (100%)	14.5±1.8 (tange 13 to 15)	X-ray Spirometry Used Bjure's equation (Cobb angle) to estimate height for predicting lung func- tions	49.2° ± 10.4° (range 40° to 91°)/ No report	Right Tx curve: apical vertebrae tranged from T7 to T11 BMI > 17.5 kg/ cm ² ($n = 54$) BMI < 17.5 kg/ cm ² ($n = 54$)	Tx Cobb angle Location of apical vertebra Number of vertebra curve Tx kyphosis (T5 to T12) %VC %FV1 %FV1 BMI	Tx Cobb angle and %VC ($r = -0.30$, $p = 0.01$) Tx Cobb angle and %VC ($r = -0.30$, $p = 0.01$) Tx Cobb angle and %FV ($r = -0.24$, $p = 0.04$) Location of apical vertebra and %FV ($r = 0.33$, $p = 0.006$) Location of apical vertebra and %FV ($r = 0.33$, $p = 0.006$) Location of apical vertebra and %FV ($r = 0.33$, $p = 0.006$) No. of vertebrae and %FV ($r = 0.34$, $p = 0.001$) No. of vertebrae and %FV ($r = -0.34$, $p = 0.003$) No. of vertebrae and %FV ($r = -0.34$, $p = 0.003$) No. of vertebrae and %FV ($r = -0.34$, $p = 0.003$) No. of vertebrae and %FV ($r = -0.34$, $p = 0.003$) No. of vertebrae and %FV ($r = -0.34$, $p = 0.004$) Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient with a lower BMI (≤ 17.5) had significantly lower %VC ($p = 0.004$), Patient vertebrae and %CC ($r = -0.34$, $p = 0.004$), Patient vertebrae and %FVC ($r = 0.34$, $p = 0.004$), Patient vertebrae independent predictors for reduced %VC, %FVC, and %FFV, which could account or 38.6K, 39.1%, and 33.0% of variance (R^3), respectively *networt for a lower 10000 of apical vertebrae involved were haden with a lower of apical vertebrae involved were haden were haden were haden to variables: BMI, curve magnitude, location of apical vertebrae involved were haden vertebrae involved were haden vertebrae involved were haden vertebrae involved vertebrae

Table 1 (co	ontinued)								
Authors	Region/ Country	Study design	No. of par- ticipants (% of female)	Age±SD (years)	Measures	Coronal/ Sagittal Tx Cobb angles±SD	Type of curve	Outcome measured	Findings
Yaszay et al. 2017 [43]	USA	Cross- sectional	163 (86.5%)	15±2	X-ray (bipla- nar) Scoliometer Spirometry	3D Tx Cobb angle range 11° to 115° si angle: -56° to 44° 3D Tx AVR: 0° to 44° 0 22° 10 29° u 98° to 98°	Tx and Lx curves: Tx curve (n = 124) Lx curve (n = 39)	Upper Tx Cobb angle Main Tx Cobb angle Kyphosis (T5 T12) Tx AVR Lx Cobb angle Lx AVR %FEV %FEV %TLC	There were significant relationships between: Upper Tx Cobb angle and %FEV ₁ ($r = -0.224$, $p < 0.05$); Upper Tx Cobb angle and %FVC ($r = -0.166$, $p < 0.05$); Main Tx Cobb angle and %FVC ($r = -0.126$, $p < 0.05$); Main Tx Cobb angle and %FVC ($r = -0.238$, $p < 0.05$); Main Tx Cobb angle and %FVC ($r = -0.238$, $p < 0.05$); TS-T12 kyphosis and % FVV ($r = -0.238$, $p < 0.05$); TS-T12 kyphosis and %FV ($r = 0.337$, $p < 0.05$); TS-T12 kyphosis and %FV ($r = 0.337$, $p < 0.05$); TS-T12 kyphosis and %FV ($r = 0.337$, $p < 0.05$); TM = 0.488, $p < 0.05$; TX ANR and %FV ($r = 0.233$, $p < 0.05$); TX ANR and %FV ($r = 0.233$, $p < 0.05$); TX ANR and %FV ($r = 0.233$, $p < 0.05$); TX ANR and %FV ($r = 0.233$, $p < 0.05$); TX ANR and %FV ($r = 0.137$, $p < 0.05$); TX ANR and %FV ($r = 0.233$, $p < 0.05$); TX ANR and %FV ($r = 0.059$); and LX ANR and %FV ($r = 0.059$); and LX ANR and %FV ($r = 0.059$); and TX ANR and %FV ($r = 0.050$); TX ANR and %TL ($r = 0.050$); TX ANR
Yu et al. 2013 [44]	China	Cross- sectional	270 (100% With brace treatment $(n = 70)$ Without brace $(n = 200)$	14.4 (range 10 to 18)	X-ray Spirometry	51.4° (range 35° to 105°)	Tx curve Lx curve Major Tx curve (apex at between T5 to T11) ($n = 166$) Thoracolum- bar/Lx curve ($n = 104$)	With or without brace treat- ment Cobb angle TX Kyphosis (T5 to T12) FVC %FVC FEV ₁ %FEV ₁	The %FVC and %FEV ₁ were significantly lower in patients with brace treatment when compared with those without brace treatment $p < 0.05$) In patients with major Tx curve ($n = 166$), those with brace treatment ($n = 48$) had significantly lower %FVC and %FEV ₁ when compared with those without brace treatment ($n = 118$) (both $p < 0.05$) A multiple linear regression analysis was performed in patients with a major Tx curve: Smaller TX kyphosis angle was an independent predictor for reduced FVC ($R^2 = 0.016$), %FVC ($R^2 = 0.546$), FEV ₁ ($R^2 = 0.015$) and %FEV ₁ ($R^2 = 0.533$ (all $p < 0.05$) Independent variables: the actual value of FVC and FEV ₁ , %FVC and %FEV ₁ , and the age at operation, height, coronal and sagittal Cobb angles of the thoracic curve, the vertebra that the major curve involved, the hours with brace wearing, and the length of brace treatment
AT <i>r</i> = angle DLCO/VA %FEF _{25-75%} expiratory itv: %FRC	e of trunk = carbon = percen volume i	k rotation; <i>i</i> monoxide ntage of pre n 1 s; %FE tage of pre	AV r = apical ve diffusion capax dicted FEF ₂₅₋₇₃ $3V_1$ = percentag dicted FRC: F ³	rtebral rotal city per liter 5%; FEF _{25%} = ge of predic VC = forced	tion; BMI=bo r of alveolar vc = The maximuu :ted FEV ₁ ; FE 'tal capacity	dy mass index; blume; %DLCC m forced expira V ₁ /FVC = ratio	DLCO = diffu NVA = percenta fory flow at 25 of FEV ₁ to F entage of pred	sion capacity age of predicte % of FVC; FH VC; %FEV ₁ /F	of the lung for carbon monoxide; %DLCO=percentage of predicted DLCO; ed DLCO/VA; $FEF_{25-75\%} = forced expiratory flow from 25\% to 75\% of FVC; F_{20\%} = The maximum forced expiratory flow at 50\% of FVC; FEV_1=forced VC=percentage of predicted FEV1/FVC; FRC=functional residual capac-x=lumbar: AVT=anical vertebra translation: MVV=maximum voluntary$

ventilation; %MVV = percentage of predicted MVV; PEF = peak expiratory flow; SPI = spinal penetration index; SVC = slow vital capacity; TK = thoracic kyphosis; TLC = total lung capacity; %TLC = percentage of predicted TCL; Tx = thoracic; VC = vital capacity; %VC = percentage of predicted VC; RV = residual volume; RV/TLC = ration of RV to TLC; %RV = percentage of predicted RV/TLC = percentage o

Description Springer

 Table 2
 Summary of significant correlation between various spinal deformities and pulmonary function parameters

Spinal deformity	Pulmonary parameter	References	Ν	Correlation, r	Cl, 95% UL	Cl, 95% LL	Р	Level of evidence
Significant negative co	orrelations							
Proximal thoracic Cobb angle	%FVC	Please refer to Sup- plementary Material eFigure 1 for meta- analysis	1029	-0.194	-0.134	-0.253	<i>P</i> <0.001	Limited evidence
	%FEV ₁	Please refer to eFigure 1 for meta- analysis	1029	-0.234	-0.175	-0.291	<i>P</i> <0.001	Limited evidence
Main thoracic Cobb angle	%FVC	Please refer to Fig. 2	2238	-0.302	-0.210	-0.388	<i>P</i> <0.001	Limited evidence
		Please refer to Fig. 3 (For multiple regression model)	965	-0.309	-0.365	-0.250	<i>P</i> <0.001	Limited evidence
	FVC	Please refer to Fig. 2	679	-0.245	-0.108	-0.374	P < 0.001	Limited evidence
	%FEV ₁	Please refer to Fig. 2	1865	-0.348	-0.243	-0.414	P < 0.001	Limited evidence
	FEV ₁	Please refer to Fig. 2	419	-0.232	-0.037	-0.410	P < 0.001	Limited evidence
	FEV ₁ /FVC	Please refer to Fig. 2	389	-0.166	-0.262	-0.067	P = 0.001	Limited evidence
	%TLC	Please refer to Fig. 2	1090	-0.183	-0.125	-0.241	P < 0.001	Limited evidence
	TLC	Please refer to Fig. 2	167	-0.302	-0.021	-0.538	P = 0.036	Limited evidence
	%VC	Please refer to Fig. 2	350	-0.272	-0.171	-0.368	P < 0.001	Limited evidence
Number of vertebrae in thoracic curve	%FVC	Please refer to eFig- ure 2	1045	-0.262	-0.215	-0.524	<i>P</i> <0.001	Limited evidence
	%FEV ₁	Please refer to eFig- ure 2	1045	-0.255	-0.159	-0.346	<i>P</i> <0.001	Limited evidence
Main thoracic apical vertebral rotation	%FVC	Please refer to eFig- ure 3	352	-0.215	-0.112	-0.314	<i>P</i> <0.001	Limited evidence
	%TLC	Please refer to eFig- ure 3	285	-0.126	-0.009	-0.240	<i>P</i> =0.035	Limited evidence
Maximum rib hump (°)	FVC	Please refer to eFig- ure 4	166	-0.225	-0.072	-0.367	<i>P</i> =0.004	Limited evidence
Lumbar lordosis	%FVC	Please refer to eFig- ure 5	861	-0.099	-0.032	-0.165	<i>P</i> =0.004	Limited evidence
	%FEV1	Please refer to eFig- ure 5	861	-0.116	-0.049	-0.182	<i>P</i> < 0.001	Limited evidence
Significant positive con	rrelations							
Main thoracic kypho- sis (T5 to T12)	%FVC	Please refer to eFig- ure 6	1079	0.180	0.432	0.151	<i>P</i> <0.001	Limited evidence
		Please refer to Fig. 3 (for multiple regression model)	1271	0.226	0.277	0.172	<i>P</i> <0.001	Limited evidence
	%FEV1	Please refer to eFig- ure 6	1079	0.193	0.365	0.007	P = 0.042	Limited evidence
		Please refer to Fig. 3 (for multiple regression model)	966	0.318	0.260	0.374	P<0.001	Limited evidence
Maximum rib cage thickness	FVC	Please refer to eFig- ure 7	166	0.377	0.562	0.155	<i>P</i> <0.001	Limited evidence
Maximum rib cage width	FVC	Please refer to eFig- ure 8	166	0.635	0.748	0.486	<i>P</i> <0.001	Limited evidence
Rib cage volume	FVC	Please refer to eFig- ure 9	166	0.784	0.838	0.716	<i>P</i> <0.01	Limited evidence

 FEV_1 = forced expiratory volume in 1 s; % FEV_1 = percentage of predicted forced expiratory volume in the first second; FVC = forced vital capacity; %FVC = percentage of predicted forced vital capacity; TLC = total lung capacity; %TLC = percentage of predicted total lung capacity; %VC = percentage of predicted vital capacity

a kyphosis angle cutoff [17, 37], and BMI [38, 42]. Two included studies compared spinal parameters based on the severity of lung impairment [41, 49].

Significant negative univariate correlations

Meta-analyses showed that proximal thoracic Cobb angles were negatively related to %FVC (r = -0.194; 95% confidence interval [95% Cl]: -0.253 to -0.134) and %FEV₁ (r = -0.234; 95% Cl: -0.291 to -0.175) (Supplementary Material eFigure 1), while main thoracic Cobb angles were negatively associated with %FVC (r = -0.302), FVC (r = -0.245), %FEV₁ (r = -0.348), FEV₁ (r = -0.232), FEV₁/FVC ratio (r = -0.166), %TLC (r = -0.183), TLC (r = -0.302), and %VC (r = -0.272) (Fig. 2). Similarly, significant negative correlations were noted between the number of involved thoracic vertebrae and %FVC (r = -0.262; 95% Cl: -0.524 to -0.215) and $\% \text{FEV}_1$ (r = -0.255; 95% Cl: -0.346 to -0.159), between main thoracic apical vertebral rotation and %FVC (r = -0.215; 95% Cl: -0.314 to -0.112) and %TLC (r = -0.126; 95% Cl: -0.240 to -0.009), between maximum rib hump and FVC (r = -0.225; 95% Cl: -0.367 to -0.072), as well as between lumbar lordosis and %FVC (r = -0.099; 95% Cl: -0.165 to -0.032) and %FEV₁ (r = -0.116; 95% Cl: -0.182 to -0.049) (Table 2; eFigures 2-5).

Significant positive univariate correlations

Thoracic kyphosis angles were positively related to %FVC (r=0.180; 95% Cl, 0.151 to 0.432) and %FEV₁(r=0.193; 95% Cl: 0.007 to 0.365) (Table 2; eFigure 6). Other metaanalyses revealed that higher rib cage thickness (r=0.377; 95% Cl: 0.155 to 0.562), width (r=0.635; 95% Cl: 0.486 to 0.748), and volume (r=0.784; 95% Cl: 0.716 to 0.838) were significantly associated with higher FVC (Table 2; eFigures 7–9).

Reported multivariate analyses

Three meta-analyses showed significant correlations between main thoracic Cobb angles and %FVC (r = -0.309), as well as between main thoracic kyphosis angles and FEV₁ (r=0.318) or %FVC (r=0.226) after adjusting for confounders (Fig. 3). These results were similar to the corresponding meta-analyses of univariate analysis (Fig. 2; eFigure 6).

Discussion

This is the first systematic review and meta-analysis to summarize the associations between various spinal parameters and pulmonary function parameters in patients with AIS. Limited-quality evidence supports that increased thoracic Cobb angles, number of involved thoracic vertebrae, apical vertebral rotation, rib hump, and lumbar lordotic angles are related to decreased %FVC, whereas increased thoracic kyphosis angles are associated with larger %FVC and %FEV₁. Rib cage parameters are positively correlated with FVC.

Scoliosis involves three-dimensional spinal deformity and thoracic cage distortion that may affect each other and worsen lung function [56]. Notably, thoracic cage deformity may alter spinal curvature, and causes rotation and shortening of the thoracic spine, leading to compromised chest wall compliance [57], decreased lung volume under the rib hump, and lung impingement on the concave side. The compressed lung tissues may reduce lung compliance, causing restrictive lung diseases [58]. Similarly, the rotational vertebral deformity may cause thoracic asymmetry [11], which increases the chest wall stiffness [59], reduces the efficiency of respiratory muscles and the diaphragm [8]. The vertebral rotation and rib hump can also cause imbalance in bilateral paraspinal and respiratory muscles [60], limiting the elevation of ribs and reducing lateral and anteroposterior movements of the thoracic cage [11]. These altered chest wall and respiratory muscle mechanics may decrease TLC [61], and increase the risk of hypercapnia, hypoxemia, and alveolar hypoventilation, causing irreversible lung atrophy [57].

While it is well known that patients with thoracic Cobb angles > 50° display clinically significant pulmonary impairments [62], our findings suggest that pulmonary impairment exists even in patients with mild-to-moderate idiopathic scoliosis [53]. However, some patients with severe spinal curvature may not show pulmonary decline if they have good apical vertebral rotational flexibility [39]. Notably, AIS patients with a flexible spine (rotational flexibility > 55%) have normal lung function [56]. Therefore, thoracic curve flexibility should be considered in evaluating the associations.

The decreased %FVC and %VC but a normal FEV₁/FVC ratio among patients with AIS in the included studies indicate that they show restrictive lung characteristics [7, 55]. However, there are conflicting findings regarding the relation between spinal deformity and obstructive lung disease in patients with AIS. While one included study reported no significant relation between main thoracic Cobb angles and FEV₁/FVC ratio [34], another included study found that 68 out of 176 AIS patients with thoracic Cobb angle > 40° had obstructive lung diseases although no significant correlation between Cobb angles and FEV₁/FVC ratio was noted [16]. The latter study also showed that 73% of these 68 patients had irreversible obstructive lung disease that could not be improved by bronchodilator [16]. Although multiple factors (e.g., lower airway malacia, asthma) may lead to obstructive lung characteristics [16], rib cage deformity-related intrathoracic airway compression or respiratory muscle weakness

Fig. 2 Forest plots of univariate meta-analysis of main thoracic Cobb angles and pulmonary parameters

Ct. de	Tatal	Completion	Lamon Limit	Unner I init	tain Thoracic	cobb rangic)	Comple		/ CI	
Akazawa et al., 2021	45	-0.353	-0.586	-0.066	-2.391	0.017	Correla	ition and 95	<u>6 CI</u>	ĩ
Daruwalla and Tan, 1985	30	-0.499	-0.728	-0.169	-2.847	0.004		_		
Gitelman et al., 1976	49	-0.410	-0.620	-0.146	-2.954	0.003	_ _ + ∎_	- 1	1	
Huh et al., 2015	81	-0.331	-0.512	-0.121	-3.038	0.002		-1	1	
Kim et al., 2005	118	-0.180	-0.349	0.001	-1.952	0.051	-		1	
Kim et al., 2007	139	0.045	-0.122	0.210	0.525	0.599		- - -	1	
Lin et al., 2021	168	-0.283	-0.417	-0.137	-3.737	0.000	-	-	1	
Machino et al., 2021	67	-0.307	-0.510	-0.072	-2.538	0.011			1	
McPhail et al., 2015 Newton et al., 2005	631	-0.096	-0.240	0.053	-1.263	0.207			1	
Szeinberg et al., 1988	24	-0.466	-0.732	-0.077	-2.314	0.021		<u> </u>	1	
Tung et al., 2018	142	-0.230	-0.380	-0.068	-2.751	0.006	_ I [⊣	-	1	
Upadhyay et al., 1995	68	-0.303	-0.505	-0.070	-2.522	0.012		-	1	
Vilamor et al., 2019	91	-0.320	-0.453	-0.122	-3.111	0.002		-	1	
Wang et al., 2019	120	-0.805	-0.874	-0.705	-9.242	0.000	_ - _		1	
Vaszav et al. 2017	163	-0.200	-0.420	-0.085	-2.878	0.004		F	1	
Total	2238	-0.302	-0.388	-0.210	-6.206	0.000	_ _ ∢		1	
Heterogeneity: : $\tau^2 = 0.032$;	$\chi^2 = 79.28$	df = 3 (p < 0.0)	001); I ² =78.56%	6			-1.00 -0.50	0.00	0.50	1.00
Meta-Analysis (Forced V	ital Capa	city and Main	Thoracic Col	bb Angle)			C 1			
Study	10tal 72	Correlation	Lower Limit	O 258	z-value	p-value	Correl	ation and 95	<u>% CI</u>	
Akazawa et al. 2021	45	-0.311	-0.554	-0.019	-2.085	0.037			1	
Bouloussa et al., 2019	54	-0.370	-0.580	-0.113	-2.774	0.006			1	
Gitelman et al., 1976	49	-0.390	-0.605	-0.122	-2.793	0.005		_	1	
Kim et al., 2007	139	0.096	-0.072	0.258	1.123	0.261	1 1-	-+∎	1	
Machino et al., 2021	67	-0.263	-0.473	-0.024	-2.155	0.031			1	
Pietton et al., 2022	45	-0.280	-0.530	0.015	-1.864	0.062			1	
Inadhyay et al. 1005	40	-0.506	-0.694	-0.253	-3.035	0.000	- -		1	
/ilamor et al., 2019	91	-0.150	-0.572	-0.178	-3.644	0.216				
lotal	679	-0.245	-0.374	-0.108	-3.447	0.001			1	
leterogeneity: $\tau^2 = 0.036$; γ	$\chi^2 = 29.51,$	df = 9 (p < 0.00	1); I ² =69.50%				-1.00 -0.50	0.00	0.50	1.00
Aeta-Analysis (The Pero	centage of	f the Predicted	Forced Expin	atory Volume	in the First Sec	ond and Main	Thoracic Cobb	Angle)	0/ 67	
Study Akazawa et al. 2021	10tal	_0 382	_0 607	-0 100	-2 608	p-value 0.009	Corre	ation and 95	70 CI	1
Daruwalla and Tan. 1985	30	-0.570	-0.772	-0.264	-3.367	0.001		_		- 1
Gitelman et al., 1976	49	-0.350	-0.575	-0.076	-2.479	0.013				
luh et al., 2015	81	-0.391	-0.561	-0.189	-3.647	0.000		_		- 1
harreborde et al., 2013	54	0.000	-0.268	0.268	0.000	1.000	-	_		- 1
Kim et al., 2005	118	-0.260	-0.421	-0.083	-2.854	0.004	-	T		- 1
in et al., 2021	168	-0.374	-0.497	-0.236	-5.049	0.000		F I		- 1
Machino et al., 2021	67	-0.123	-0.353	0.121	-0.989	0.323	- 1 - 17			- 1
McPhail et al., 2015	176	-0.131	-0.274	0.017	-1.739	0.082				- 1
Newton et al., 2005	631	-0.293	-0.363	-0.220	-7.564	0.000	1 14			- 1
lamor et al., 2019	91	-0.350	-0.519	-0.155	-3.428	0.001	_ ⊢ ∎	⊢		- 1
Wang et al., 2019	72	-0.812	-0.878	-0.715	-9.416	0.000	_ + -	_		- 1
V		0.240	0.400	A A 44		0.008		-		- 1
Au et al., 2015	120	-0.240	-0.402	-0.063	-2.648	0.000	1 12			
Yaszay et al., 2017	120	-0.240	-0.402 -0.523	-0.063	-2.648 -5.374	0.000				
Yaszay et al., 2015 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; 7	120 163 1865 $\chi^2 = 67.08$,	-0.240 -0.401 -0.348 , df = 13 (p < 0.0	-0.402 -0.523 -0.414 001); I ² =80.6%	-0.063 -0.264 -0.243	-2.648 -5.374 -6.213	0.000	-1.00 -0.50	0.00	0.50	 1.0
Au et al., 2015 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study	120 163 1865 $\chi^2 = 67.08$, Expiratory <u>Total</u> 73	-0.240 -0.401 -0.348 , df = 13 (p < 0.4 y Volume in th <u>Correlation</u> 0.030	-0.402 -0.523 -0.414 001); I ² =80.6% he First Second Lower Limit	-0.063 -0.264 -0.243 d and Main The <u>Upper Limit</u> 0.258	-2.648 -5.374 -6.213 pracic Cobb Ai <u>z-value</u> 0.251	0.000 0.000 0.000 ngle) <u>p-value</u> 0.802	-1.00 -0.50	0.00	0.50	1.0
Xu et al., 2015 Yaszay et al., 2017 Total Heterogeneity: τ ² = 0.035; ; Meta-Analysis (Forced F <u>Study</u> Abdelaal et al., 2018 & kazawa et al., 2021	120 163 1865 $\chi^2 = 67.08$, Expiratory Total 73 45	-0.240 -0.401 -0.348 , df = 13 ($p < 0.9$ y Volume in th <u>Correlation</u> 0.030 -0.352	-0.402 -0.523 -0.414 001); 1 ² =80.6% Lower Limit -0.201 -0.585	-0.063 -0.264 -0.243 d d and Main Thu Upper Limit 0.258 -0.065	-2.648 -5.374 -6.213 oracic Cobb Ar <u>z-value</u> 0.251 -2.383	0.000 0.000 ngle) p-value 0.802 0.017	-1.00 -0.50	0.00	0.50	 1.0
Au et al., 2015 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; 7 Meta-Analysis (Forced F Study Abdelaal et al., 2018 Vkazawa et al., 2021 Jitchman et al., 1976	$120 \\ 163 \\ 1865 \\ \chi^2 = 67.08, \\ Expiratory \\ Total \\ 73 \\ 45 \\ 49$	-0.240 -0.401 -0.348 , df = 13 ($p < 0.9$ y Volume in th Correlation 0.030 -0.352 -0.420	-0.402 -0.523 -0.414 001); I ² =80.6% he First Second Lower Limit -0.201 -0.585 -0.627	-0.063 -0.264 -0.243 d and Main The Upper Limit 0.258 -0.065 -0.157	-2.648 -5.374 -6.213 oracic Cobb At z-value 0.251 -2.383 -3.036	0.000 0.000 ngle) p-value 0.802 0.017 0.002	-1.00 0.50	0.00	0.50	 1.0
Au et al., 2015 Yaszay et al., 2017 Total Heterogeneity: τ ² = 0.035; ; Meta-Analysis (Forced E Study Videlaal et al., 2018 Vkazawa et al., 2021 ittelman et al., 1976 tim et al., 2007	$120 \\ 163 \\ 1865 \\ \chi^2 = 67.08, \\ \hline Expiratory \\ \hline Total \\ 73 \\ 45 \\ 49 \\ 139 \hline$	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ \text{, df} = 13 \ (p < 0.40) \\ \textbf{y Volume in th} \\ \hline \\ $	-0.402 -0.523 -0.414 001); I ² =80.6% he First Second Lower Limit -0.201 -0.585 -0.627 -0.129	-0.063 -0.264 -0.243 d and Main Th- <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203	-2.648 -5.374 -6.213 oracic Cobb At <u>z-value</u> 0.251 -2.383 -3.036 0.443	0.000 0.000 p-value 0.802 0.017 0.002 0.658	-1.00 -0.50	0.00	0.50	 1.0
Au et al., 2015 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; 7 Meta-Analysis (Forced E Study Abdelaal et al., 2018 Kuszawa et al., 2021 Stiefman et al., 1976 Gim et al., 2021	$120 \\ 163 \\ 1865 \\ \chi^2 = 67.08, \\ \hline Total \\ 73 \\ 45 \\ 49 \\ 139 \\ 67 \\ 77 \\ 139 \\ 67 \\ 73 \\ 139 \\ 67 \\ 73 \\ 139 \\ 67 \\ 73 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 67 \\ 139 \\ 130 \\ 13$	-0.240 -0.348 -0.348 , df = 13 (p < 0.9) y Volume in th <u>Correlation</u> 0.030 -0.352 -0.420 0.038 -0.277	-0.402 -0.523 -0.414 001); I ² =80.6% te First Secont Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485	-0.063 -0.264 -0.243 d and Main The Upper Limit 0.258 -0.065 -0.157 0.203 -0.039	-2.648 -5.374 -6.213 oracic Cobb At z-value 0.251 -2.383 -0.036 0.443 -2.275	0.000 0.000 ngle) p-value 0.802 0.017 0.002 0.658 0.023	-1.00 -0.50	0.00	0.50	1.0
Au et al., 2013 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study Vadelaal et al., 2018 Vadelaal, 2018 Vadelaal, 2018 Vadelaal, 2021 Jitchana et al., 2021 Jiaching et al., 2021 Jiaravira et al., 2017	$120 \\ 163 \\ 1865 \\ \chi^2 = 67.08, \\ \hline xpiratory \\ \hline Total \\ 73 \\ 45 \\ 49 \\ 139 \\ 67 \\ 46 \\ 419 \\ \hline xum \\ 40 \\ 40 \\ 40 \\ 40 \\ 40 \\ 40 \\ 40 \\ 40$	-0.240 -0.401 -0.348 df = 13 (p < 0.1 y Volume in th <u>Correlation</u> 0.030 -0.352 -0.420 0.038 -0.277 -0.462 0.332	-0.402 -0.523 -0.414 001); I ² =80.6% Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 0.410	-0.063 -0.264 -0.243 d and Main The <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203 -0.039 -0.039 -0.198 0.037	-2.648 -5.374 -6.213 bracic Cobb A 1 z -2.383 -3.036 0.443 -2.275 -3.278 2.310	0.000 0.000 0.000 0.000 0.802 0.017 0.002 0.658 0.023 0.001 0.020	-1.00 -0.50	0.00	0.50	1.0
Nu et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study Vdelaal et al., 2018 Vkazawa et al., 2021 Jinchman et al., 2021 Jinchma et al., 2017 Total Eteropeneity: : $\tau^2 = 0.045$;	$\frac{120}{163}$ 1865 2xpiratory Total 73 45 49 139 67 46 419 $x^2 = 19.35$	-0.240 -0.401 -0.348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0.352 -0.420 0.038 -0.352 -0.420 0.038 -0.277 -0.462 -0.232 0, df = 5 ($p = 0.1$	-0.402 -0.523 -0.414 0011; I ² =80.6% te First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0022; I ² =74.2%	-0.063 -0.264 -0.243 5 d and Main Thu <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -2.319	0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020	-1.00 0.50	0.00	0.50	1.0
Au et al., 2015 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; 7 Meta-Analysis (Forced E Study Vabelaal et al., 2018 Vaszawa et al., 2021 intelman et al., 2021 internan et al., 2021 iaravira et al., 2021 iaravira et al., 2017 Total Heterogeneity: : $\tau^2 = 0.045$; Mata-Analyzis (Exceed 1)	$\frac{120}{163}$ 1865 $\chi^2 = 67.08,$ Expiratory Total 73 45 49 139 67 46 419 $\chi^2 = 19.35$	-0.240 -0.401 -0.348 df = 13 (p < 0.4) y Volume in th <u>Correlation</u> 0.030 -0.352 -0.420 0.038 -0.277 -0.462 -0.232 0, df = 5 (p = 0.6)	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second <u>Lower Limit</u> -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2%	-0.063 -0.264 -0.243 is d and Main Th <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -2.319	0.000 0.000 0.000 0.000 0.000 0.017 0.002 0.658 0.023 0.001 0.020	-1.00 -0.50	0.00	0.50	1.0
Nu et al., 2013 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; 7 Meta-Analysis (Forced E Study kbdelaal et al., 2018 kuszawa et al., 2018 kuszawa et al., 2021 ittc]man et al., 2021 ittc]man et al., 2021 ittc]man et al., 2021 ittc]man et al., 2017 fotal Heterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I Study	120 163 1865 $\chi^2 = 67.08$, Expiratory Total 73 45 49 139 67 46 419 $\chi^2 = 19.35$ Expiratory Total	-0.240 -0.401 -0.348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0.352 -0.420 0.038 -0.277 -0.462 -0.232 P, df = 5 ($p = 0.0$ y Volume in th Correlation	-0.402 -0.523 -0.414 0001); I ² =80.6% the First Second <u>Lower Limit</u> -0.201 -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.663 -0.410 0002); I ² =74.2% the First Second Lower Limit	-0.063 -0.264 -0.243 d and Main Thu Upper Limit 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 d to the Forced Upper Limit	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -2.319 Vital Capacity z-value	0.000 0.000 0.000 0.000 0.000 0.017 0.002 0.658 0.023 0.001 0.020 v Ratio and Mz	-1.00 -0.50	ation and 95	0.50 <u>% CI</u> 0.50 0.50	1.0
ku et al., 2013 fotal feterogeneity: $\tau^2 = 0.035$; ; feta-Analysis (Forced E Study b feterogeneity: $\tau^2 = 0.035$; ; feta-Analysis (Forced I s feta-Analysis (Forced I Study in et al., 2021 b feta-Analysis (Forced I s feta-Analysis (Forced I s feta-Analysis (Forced I s study in et al., 2021	$120 \\ 163 \\ 1865 \\ \chi^2 = 67.08, \\ \hline xpiratory \\ \hline Total \\ 73 \\ 45 \\ 49 \\ 139 \\ 67 \\ 46 \\ 419 \\ \chi^2 = 19.35 \\ \hline Expirator \\ \hline Total \\ \hline 168 \\ \hline$	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ \text{ot} = 13 \ (p < 0.1) \\ \text{y Volume in th} \\ \hline \text{Correlation} \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ \text{ot} = 5 \ (p = 0.0) \\ \text{y Volume in th} \\ \hline \text{Correlation} \\ \hline \text{Correlation} \\ -0.215 \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.410 -0.410 0022); I ² =74.2% be First Second Lower Limit -0.355	-0.063 -0.264 -0.243 d and Main Thr <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 d to the Forced <u>Upper Limit</u> -0.066	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.001 0.020 v Ratio and Ma <u>p-value</u> 0.005	-1.00 -0.50	0.00	0.50 <u>** CI</u> 0.50 <u>** CI</u>	1.0
ku et al., 2013 fotal feterogeneity: $\tau^2 = 0.035$; τ feta-Analysis (Forced E Study Medical et al., 2018 kazawa et al., 2021 kazawa et al., 2021 kazawa et al., 2021 inter et al., 2007 faching et al., 2021 arawira et al., 2017 otal leterogeneity: $\tau^2 = 0.045$; Meta-Analysis (Forced I Study <i>in</i> et al., 2021 <i>kel</i> (Phail, 2015)	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08,\\ \end{array}$	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ \text{of} = 13 \ (p < 0.49 \\ \text{o} < 0.328 \\ -0.322 \\ -0.420 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.030 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0. \text{of} = 5 \ (p = 0.49 \\ \text{o} < 0.238 \\ -0.218 \\ -0.215 \\ -0.218 \\ -0.218 \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second <u>Lower Limit</u> -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% are First Second <u>Lower Limit</u> -0.355 -0.271	-0.063 -0.264 -0.243 5 d and Main Thr <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 d to the Forced <u>Upper Limit</u> -0.066 0.020	-2.648 -5.374 -6.213 oracic Cobb A: <u>z-value</u> 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity <u>z-value</u> -2.805 -1.696	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 v Ratio and Ma <u>p-value</u> 0.005 0.090	-1.00 -0.50	lation and 95 	 0.50 <u>% C1</u> 0.50	 1.0 1.0
Nu et al., 2013 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study kbdelaal et al., 2018 kuszawa et al., 2018 kuszawa et al., 2021 Meta-Analysis (Forced I Study Meta-Analysis (Forced I Study Meta-Analysis (Forced I Study Animet al., 2021 Meta-Analysis (Forced I Study Signa (Forced I Study Meta-Analysis (Forced I Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08,\\ \end{array}$	-0.240 -0.401 -0.348 df = 13 (p < 0.1 y Volume in th <u>Correlation</u> -0.352 -0.420 -0.352 -0.420 -0.322 -0.420 -0.232 df = 5 (p = 0.1 <u>Correlation</u> -0.215 -0.215 -0.215 -0.128 -0.130	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second <u>Lower Limit</u> -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% are First Second Lower Limit -0.355 -0.271 -0.408	-0.063 -0.264 -0.243 is d and Main The <u>Upper Limit</u> 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 d to the Forced <u>Upper Limit</u> -0.066 -0.037	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.023 0.001 0.020 v Ratio and M 2 p-value 0.005 0.000 0.02	-1.00 -0.50	ation and 95 ation ation atio	 0.50 <u>% C1</u> 0.50	1.0
stat at al., 2013 aszay et al., 2017 otal leterogeneity: $\tau^2 = 0.035$; ; feta-Analysis (Forced E Study bdelaal et al., 2018 kazawa et al., 2021 inic et al., 2021 asching et al., 2017 otal eterogeneity: : $\tau^2 = 0.045$; feta-Analysis (Forced I Study in et al., 2021 istema et al., 2021 istema et al., 2022 otal	120 163 1865 $\chi^2 = 67.08$, Expiratory Total 73 49 139 67 46 419 $\chi^2 = 19.35$ Expirator Total 168 168 168 168 168 45 389 $\chi^2 = 29.52$	-0.240 -0.401 -0.348 df = 13 (p < 0.0 y Volume in th <u>Correlation</u> -0.352 -0.420 -0.330 -0.420 -0.420 -0.420 -0.420 -0.232 -0.462 -0.232 -0.462 -0.232 -0.462 -0.215 -0.128 -0.130 -0.166 df = 9 (n < 0.00)	-0.402 -0.523 -0.414 0001); I ² =80.6% the First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.410 0022); I ² =74.2% the First Second Lower Limit -0.355 -0.271 -0.268 -0.271 -0.266 -0.271 -0.266 -0.271 -0.266 -0.271 -0.266 -0.271 -0.266 -0.271 -0.266 -0.271 -0.266 -0.271 -0.265 -0.271 -0.265 -0.271 -0.265 -0.271 -0.265 -0.271 -0.355 -0.271 -0.260 -0.275 -0.271 -0.355 -0.271 -0.355 -0.271 -0.260 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.408 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.408 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.355 -0.271 -0.260 -0.271 -0.355 -0.271 -0.260 -0.271 -0.355 -0.271 -0.260 -0.271 -0.260 -0.355 -0.271 -0.260 -0.271 -0.260 -0.271 -0.408 -0.260 -0.271 -0.260 -0.271 -0.260 -0.271 -0.260 -0.271 -0.260 -0.271 -0.260 -0.271 -0.260 -0.271 -0.260 -0.271 -0.260 -0.275 -0.276 -0.260 -0.275 -0.260 -0.260 -0.275 -0.260	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 -0.037 -0.037 -0.037 -0.066 -0.170 -0.066	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274	0.000 0.000 0.000 p-value 0.802 0.658 0.002 0.658 0.002 0.002 0.001 0.020 v Ratio and Ma p-value 0.005 0.090 0.397 0.001	-1.00 -0.50	ation and 95 0.00 ation and 95 0.00 bb Angle) ation and 95 ationation ation ation ation ation ation ation a	0.50 <u>** CI</u> 0.50 <u>** CI</u>	1.0
ku et al., 2013 fotal Heterogeneity: $\tau^2 = 0.035$; γ feta-Analysis (Forced E Study Medical et al., 2018 kazawa et al., 2021 kazawa et al., 2021 itiziman et al., 2021 faching et al., 2021 aravira et al., 2017 otal leterogeneity: $\tau^2 = 0.045$; Meta-Analysis (Forced I Study <i>in</i> et al., 2021 <i>ice</i> <i>in</i> et al., 2021 <i>ice</i> <i>in</i> et al., 2021 <i>ice</i> <i>in</i> et al., 2022 <i>ice</i> <i>in</i> et al., 2022 <i>ice</i> <i>in</i> et al., 2022 <i>ice</i> <i>in</i> et al., 2023 <i>ice</i> <i>in</i> et al., 2023 <i>ice</i> <i>in in in in in in in in</i>	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08,\\ \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ \text{o} & \text{df} = 13 \ (p < 0.49\\ \text{volume in th}\\ \hline & \text{Correlation}\\ 0.030\\ -0.352\\ -0.420\\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ \text{o} & \text{d} = 5 \ (p = 0.49\\ \text{volume in th}\\ \hline & \text{Correlation}\\ -0.215\\ -0.128\\ -0.128\\ -0.130\\ -0.166\\ \text{df} = 9 \ (p < 0.00\\ \text{df} = 0 \ (p < 0.00\ (p < 0.00\ (p < 0.00\ (p < 0.00\ (p < 0$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% are First Second Lower Limit -0.355 -0.271 -0.408 -0.271 -0.408 -0.262 -0.271 -0.408 -0.262	-0.063 -0.264 -0.243 -0.243 -0.065 -0.065 -0.157 -0.065 -0.157 -0.039 -0.198 -0.037 -0.037 -0.037 -0.037 -0.037 -0.066 -0.0667	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 / Ratio and Ma p-value 0.005 0.090 0.397 0.001	-1.00 -0.50	lation and 95	0.50	 1.0 1.0
Nu et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E <u>Study</u> bdelaal et al., 2018 kazawa et al., 2018 ikiciman et al., 2021 ikiciman et al., 2021 Gachino et al., 2021 Gachino et al., 2021 Feterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I <u>Study</u> Lim et al., 2021 Methal., 2021 Study Coll Study Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Pered	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$ Expirator: Total 73 45 49 139 67 46 419 $\chi^2 = 19.35$ Expirator: Total 168 176 45 389 $\chi^2 = 29.51, \end{array}$	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ 0.0348 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.232 \\ 0. df = 5 (p = 0.4) \\ 0.0215 \\ -0.128 \\ -0.160 \\ df = 9 (p < 0.00 $	-0.402 -0.523 -0.414 0001); I ² =80.6% he First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0022); I ² =74.2% he First Second Lower Limit Lower Limit -0.251 -0.425 -0.452 -0.452 -0.453 -0.410 0022); I ² =69.5%	-0.063 -0.264 -0.243 5 d and Main Thu Upper Limit 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 d to the Forced Upper Limit -0.066 0.020 0.170 -0.067 Capacity and M	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.023 0.001 0.020 v Ratio and Ma p-value 0.005 0.005 0.005 0.000 0.397 0.001 cobb Angle	-1.00 -0.50	ation and 95	0.50	 1.0 1.0
Nu et al., 2013 Yatsay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study Vdelaal et al., 2018 Vacava et al., 2021 Jight and al., 2021 Jight achino et al., 2021 Jight achino et al., 2021 Jight achino et al., 2021 Yata achino et al.	$\frac{120}{163}$ $\frac{1865}{1865}$ $\frac{2}{7} = 67.08,$ $\frac{2}{73}$ $\frac{73}{45}$ $\frac{4}{45}$ $\frac{4}{9}$ $\frac{139}{2} = 19.35$ $\frac{7}{2} = 19.35$ $\frac{1}{68}$ $\frac{1}{7} = 10.35$ $\frac{1}{2} = 10$	$\begin{array}{r} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ + 0.0348 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.227 \\ -0.462 \\ 0.038 \\ -0.277 \\ -0.462 \\ 0.038 \\ -0.215 \\ -0.128 \\ -0.108 \\ -0.166 \\ df = 9 \ (p < 0.000 \\ f \ the Predicted \\ Correlation \\ 0.000 \\ \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.410 -0.201 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.410 -0.402 -0.458 -0.627 -0.412 -0.412 -0.412 -0.402 -0.414 -0.201 -0.402 -0.458 -0.627 -0.412 -0.412 -0.402 -0.412 -0.410 -0.410 -0.402 -0.412 -0.410 -0.410 -0.402 -0.412 -0.410 -0.402 -0.402 -0.410 -0.402 -0.222 -0.402 -0.222 -0.402 -0.222 -0.402 -0.222 -0.408 -0.2262 -0.50%	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 -0.037 -0.037 -0.066 -0.170 -0.066 -0.170 -0.067 -0.067	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000	0.000 0.000 0.000 p-value 0.802 0.658 0.002 0.658 0.002 0.001 0.023 0.001 0.020 v Ratio and Mz p-value 0.005 0.090 0.397 0.001 Cobb Angle p-value 1.000	-1.00 -0.50	ation and 95 0.00 0.00 0.00 0.00 bb Angle) 1ation and 95 0.00 1ation and 95 1 1 1 1 1 1 1 1 1 1 1 1 1	0.50 % CI 0.50 % CI 0.50 % CI	 1.0 1.0
Nu et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; γ Meta-Analysis (Forced F Study Videlaal et al., 2018 Vacava et al., 2018 Vacava et al., 2021 Jinelman et al., 1976 Jine et al., 2021 Jine et al., 2021 Analysis (Forced F Study Methail, 2015 Section et al., 2021 Methail, 2015 Section et al., 2022 Total Heterogeneity: $\tau^2 = 0.036$; γ Meta-Analysis (The Pere- Study Iharreborde et al., 2013 WePhail et al., 2013	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ 0.0348 \\ 0.030 \\ -0.322 \\ -0.420 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0.046 \\ -0.232 \\ 0.046 \\ -0.215 \\ -0.128 \\ -0.128 \\ -0.128 \\ -0.166 \\ 0.000 \\ -0.000 \\ -0.077 \\ \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.125 -0.663 -0.410 0002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.262 -0.262 Lower Limit -0.268 -0.268 -0.268 -0.261 -0.268 -0.2	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.039 -0.039 -0.039 -0.037 -0.039 -0.037 -0.037 -0.037 -0.037 -0.04 -0.037 -0.04 -0.020 -0.020 -0.065 -0.170 -0.065 -0.170 -0.065 -0.170 -0.067 -0.268 -0.024 -0.028 -0.028 -0.028 -0.028 -0.024 -0.024 -0.026 -0.024 -0.026 -0.024 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.264 -0.265 -0.065 -0.157 -0.039 -0.039 -0.037 -0.045 -0.055 -0.055 -0.055 -0.055 -0.055 -0.055 -0.055 -0.055 -0.055 -0.055 -0.055 -0.057 -0.0	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -0.044 -2.383 -0.243 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 (Ratio and Mz p-value 0.005 0.090 0.397 0.001 2.06b Angle) p-value 1.000 0.023	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 	 1.0 1.0
Nu et al., 2013 (aszay et al., 2017 Total Total Teterogeneity: $\tau^2 = 0.035$; ; feta-Analysis (Forced E <u>Study</u> (bdelaal et al., 2018 (kazawa et al., 2011 (kazawa et al., 2021) (kitzmar et al., 2021) (achino et al., 2021) (bdelaal, 2021) (achino et al., 2022) (achino et al., 2023) (achino et al., 2023)	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$ Expiratory Total 73 45 49 139 67 46 419 $\chi^2 = 19.35$ Expirator Total 168 176 45 389 $\chi^2 = 29.51, $ centage of Total 54 174 631	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ + 0.0348 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.420 \\ -0.232 \\ 0. df = 5 (p = 0.4) \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0. df = 5 (p = 0.4) \\ 0.016 \\ -0.128 \\ -0.106 \\ -0.166 \\ df = 9 (p < 0.00 \\ 0.016 \\ -0.172 \\ -0.193 \\ \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% the First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% the First Second Lower Limit -0.265 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.265 -0.313 -0.313 -0.365 -0.323 -0.325 -0.265 -0.323 -0.325 -0.265 -0.323 -0.325 -0.265 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.325 -0.275 -0.265 -0.275 -0.275 -0.265 -0.275 -0.265 -0.275 -0.265 -0.275 -0.266 -0.265 -0.275 -0.266 -0.265 -0.275 -0.266 -0.265 -0.275 -0.266 -0.266 -0.265 -0.255	-0.063 -0.264 -0.243 5 d and Main Thu Upper Limit -0.065 -0.157 -0.039 -0.198 -0.037 d to the Forced Upper Limit -0.066 0.020 0.170 -0.067 Capacity and M Upper Limit 0.268 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.171	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.002 0.002 0.002 0.002 0.002 0.000 0.397 0.001 200b Angle p-value 1.000 0.023 0.001	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50	 1.0 1.0
All et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study Voldenal et al., 2018 Vacawa et al., 2021 Jingham et al., 2021 Jingham et al., 2021 Jingham et al., 2021 Jingham et al., 2021 Meta-Analysis (Forced I Study Lin et al., 2021 Meta-Analysis (Forced I Study Lin et al., 2021 Meta-Analysis (The Pert Study Meta-Analysis (The Pert Study Meta-Analysis (The Pert Study Meta-Analysis, 2013 Meta-Analysis, 2021 Meta-Analysis, 2021 Study Meta-Analysis, 2021 Meta-Analysis, 2021 Meta-Analysis, 2021 Meta-Analysis, 2021 Meta-Analysis, 2021 Meta-Analysis, 2021 Meta-Analysis, 2025 Diagadaya et al., 2005 Newton et al., 2005 Upadhaya et al., 2005 Study	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ df = 13 \ (p < 0.1) \\ y \ Volume in th \\ \hline correlation \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0.130 \\ -0.166 \\ df = 9 \ (p < 0.000 \\ f \ the \ Predicted \\ \hline correlation \\ 0.000 \\ -0.172 \\ -0.193 \\ -0.190 \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.627 -0.410 2021; I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.268 -0.265 -0.313 -0.267 -0.313 -0.267 -0.313 -0.267 -0.410	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 -0.037 -0.037 -0.037 -0.037 -0.066 -0.020 -0.020 -0.0667 -0.020 -0.020 -0.0667 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.026 -0.020 -0.026 -0.026 -0.026 -0.026 -0.026 -0.027 -0.065 -0.027 -0.065 -0.027 -0.065 -0.027 -0.065 -0.057 -0.055	-2.648 -5.374 -6.213 bracic Cobb A: z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.001 0.023 0.001 0.020 v Ratio and Ma p-value 0.005 0.090 0.397 0.001 cobb Angle) p-value 1.000 0.023 0.001	-1.00 -0.50	ation and 95 ation ation ationation ation ation ation ation ation ation ation ation ation ati	 0.50 % <u>CI</u> 0.50 % <u>CI</u> 0.50	 1.0 1.0
Au et al., 2017 Yeta-Analysis (Forced F Study Videlaat et al., 2018 Yeta-Analysis (Forced F Study Videlaat et al., 2018 Vacava et al., 2021 Videlaat et al., 2021 Yeta-Analysis (Forced F Study McPhail., 2015 Yetton et al., 2021 McPhail., 2015 Yetton et al., 2021 McPhail., 2015 Yetton et al., 2021 McPhail., 2015 Yetton et al., 2021 McPhail., 2015 Yetton et al., 2021 Newton et al., 2013 Wethal., 2015 Yetton et al.,	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ , df = 13 \ (p < 0.4)\\ y \ Volume in th\\ \hline Correlation\\ 0.030\\ -0.352\\ -0.420\\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ 0. df = 5 \ (p = 0.4)\\ y \ Volume in th\\ \hline Correlation\\ -0.215\\ -0.128\\ -0.130\\ -0.166\\ df = 9 \ (p < 0.00\\ f \ the Predicted\\ \hline Correlation\\ 0.000\\ -0.172\\ -0.193\\ -0.190\\ -0.212\end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% are First Second Lower Limit -0.355 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.268 -0.268 -0.268 -0.313 -0.267 -0.410 -0.268 -0.313 -0.267 -0.410 -0.354 -0.261 -0.268 -0.313 -0.267 -0.410 -0.354 -0.261 -0.354 -0.261 -0.268 -0.313 -0.261 -0.410 -0.354 -0.261 -0.261 -0.261 -0.354 -0.261 -0.261 -0.261 -0.354 -0.261 -0.261 -0.261 -0.354 -0.261 -0.261 -0.261 -0.354 -0.261 -0.354 -0.261 -0.261 -0.354 -0.261 -0.354 -0.261 -0.262 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.261 -0.261 -0.354 -0.261 -0.261 -0.261 -0.354 -0.261 -0.354 -0.261 -0.354 -0.261 -0.261 -0.354 -0.265 -0.261 -0.354 -0.265 -0.410 -0.354 -0.265 -0.410 -0.354 -0.265 -0.410 -0.354 -0.265 -0.410 -0.354 -0.265 -0.410 -0.354 -0.265 -0.410 -0.354 -0.254 -0.254 -0.254 -0.255 -0.410 -0.354 -0.254 -0.254 -0.254 -0.255 -0.410 -0.354 -0.254 -0.254 -0.254 -0.255 -0.254 -0.255 -0.254 -0.255	-0.063 -0.264 -0.243 -0.243 -0.065 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 d to the Forced <u>Upper Limit</u> -0.066 0.020 0.170 -0.067 Capacity and M <u>Upper Limit</u> 0.268 -0.064 -0.067	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -0.044 -2.383 -0.2475 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 v Ratio and M 2 p-value 0.005 0.020 v Pathematical State 0.005 0.090 0.397 0.001 v State p-value 1.000 0.023 0.001 v State 1.000 0.023 v State 1.000 0.005 1.000 0.001 1.000 0.002 1.000 0.002 1.000 0.002 1.000 0.005 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.00 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.0000 1.000 1.0000 1.000 1.000 1.000 1.0	-1.00 -0.50	ation and 95	 0.50 0.50 0.50 0.50	1.0
Aut et al., 2013 fotal feterogeneity: $\tau^2 = 0.035$; ; feta-Analysis (Forced E Study bdelaal et al., 2018 kazawa et al., 2018 ikazawa et al., 2021 ikitikana et al., 2021 fachine et al., 2021 feterogeneity: : $\tau^2 = 0.045$; feta-Analysis (Forced I Study in et al., 2021 feterogeneity: $\tau^2 = 0.036$; ; feta-Analysis (The Pere Study iharebonde et al., 2013 feremogeneity: $\tau^2 = 0.036$; ; feta-Analysis (The Pere Study iharebonde et al., 2013 feremogeneity: $\tau^2 = 0.136$; ; feta-Analysis (The Pere Study iharebonde et al., 2015 ipadhyay et al., 2015 ipadhyay et al., 2017 iotal	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$ Expirator: Total 73 45 49 139 67 46 419 $\chi^2 = 19.35$ Expirator: Total 168 176 45 389 $\chi^2 = 29.51, \end{array}$ centage of Total 54 173 68 168 174 63 198 46 198 46 198 46 198 46 198 46 198 46 198 46 198 46 198 46 198 46 198 46 198 198 198 198 198 198 198 198	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ df = 13 \ (p < 0.1 \\ v \ Volume in th \\ \hline Correlation \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.232 \\ 0. df = 5 \ (p = 0.4 \\ v \ Volume in th \\ \hline Correlation \\ -0.215 \\ -0.128 \\ -0.160 \\ df = 9 \ (p < 0.00 \\ f \ the Predicted \\ \hline Correlation \\ 0.000 \\ -0.172 \\ -0.193 \\ -0.193 \\ -0.183 \\ (n = 0.740) \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% le First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% le First Second Lower Limit -0.355 -0.271 -0.402 -0.402 -0.402 -0.402 -0.402 -0.402 -0.402 -0.402 -0.410 -0.355 -0.2271 -0.268 -0.313 -0.267 -0.241 -	-0.063 -0.264 -0.243 5 4 and Main Thu Upper Limit 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 d to the Forced Upper Limit -0.066 0.020 0.170 -0.067 Capacity and M Upper Limit 0.268 -0.024 -0.051 -0.051 -0.051 -0.060 -0.125	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.002 0.023 0.001 0.020 v Ratio and M p-value 0.005 0.090 0.397 0.001 cobb Angle) p-value 1.000 0.023 0.001 cobb Angle) p-value 1.000 0.023 0.001 cobb Angle) p-value 1.000 0.023 0.001 cobb Angle) p-value 1.000 0.023 0.001 cobb Angle) p-value 1.000 0.005 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000 0.00000000	-1.00 -0.50	ation and 95	0.50 % CI 0.50 % CI 0.50	 1.0 1.00
All et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; γ Meta-Analysis (Forced F Study Volealat et al., 2018 Volealat et al., 2018 Volealat et al., 2017 Jinelman et al., 1976 Jine et al., 2007 dachino et al., 2021 intervise et al., 2021 intervise et al., 2021 Voleat-Analysis (Forced F Study Voleat-Analysis (Forced F Study Voleat-Analysis (Forced F Study VoleAnalysis (The Pereformation 1995 Study Iharreborde et al., 2017 Jotal Heterogeneity: $\tau^2 = 0.036$; γ Meta-Analysis (The Pereformation 1995 Study Study Study Iharreborde et al., 2017 Study Iharreborde et al., 2017 Study Iharreborde et al., 2017 Study Iharreborde et al., 2017 Study Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision Intervision	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ , df = 13 \ (p < 0.4)\\ y \ Volume in th\\ \hline Correlation\\ 0.030\\ -0.352\\ -0.420\\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ -0.128\\ -0.128\\ -0.128\\ -0.130\\ -0.168\\ df = 9 \ (p < 0.00\\ f \ the Predicted\\ \hline Correlation\\ 0.000\\ -0.172\\ -0.193\\ -0.183\\ 4 \ (p = 0.740); \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.653 -0.410 -0.410 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.262 -0.271 -0.408 -0.262 -0.271 -0.408 -0.262 -0.264 -0.262 -0.264 -0.262 -0.264 -0.264 -0.262 -0.264 -0.244 -0.264 -0.264 -0.244 -0.264 -0.244 -0.264 -0.244 -0.264 -0.244 -0.244 -0.264 	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.037 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.04 -0.037 -0.066 -0.020 -0.066 -0.026 -0.067 -0.067 -0.068 -0.024 -0.067 -0.067 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.055 -0.057 -0.057 -0.057 -0.057 -0.057 -0.055 -0.	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -0.0443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.773 -6.084	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 v Ratio and M 2 p-value 0.005 0.005 0.000 0.397 0.001 p-value 1.000 0.003 0.001 p-value 1.000 0.023 0.001 0.005 0.005 0.001 0.005 0.000 0.000 0.001 0.005 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.00000 0.0000000 0.00000000	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50	 1.0 1.00
Nu et al., 2013 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study Videlaal et al., 2018 Varian et al., 2021 aravira et al., 2021 aravira et al., 2021 aravira et al., 2021 Gachino et al., 2021 Total Ieterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I Study in et al., 2021 Vieta-Analysis (The Pert Study Meta-Analysis (The Pert Study Meta-Analysis (Total Lu Study	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	-0,240 -0,401 -0,348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0,352 -0,420 -0,352 -0,420 -0,232 , df = 5 ($p = 0.1$ y Volume in th <u>Correlation</u> -0,215 -0,128 -0,128 -0,130 -0,166 df = 9 ($p < 0.000$ f the Predicted <u>Correlation</u> -0,193 -0,193 -0,193 -0,190 -0,212 -0,183 4 ($p = 0.740$); :tity and Main <u>Correlation</u>	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.410 -0.201 -0.410 -0.410 -0.201 -0.410 -0.211 -0.408 -0.262 -0.410 -0.262 -0.211 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.271 -0.408 -0.265 -0.267 -0.408 -0.265 -0.271 -0.408 -0.265 -0.267 -0.408 -0.267 -0.408 -0.267 -0.408 -0.267 -0.408 -0.267 -0.408 -0.267 -0.408 -0.267 -0.267 -0.408 -0.267 -0.267 -0.271 -0.408 -0.267 -0.267 -0.267 -0.267 -0.271 -0.408 -0.267 -0.267 -0.267 -0.271 -0.408 -0.267 -0.267 -0.267 -0.267 -0.267 -0.271 -0.268 -0.267 -0.271 -0.267 -0.267 -0.267 -0.241 I ² =0.00%	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 -0.039 -0.198 -0.037 -0.039 -0.198 -0.037 -0.066 -0.020 -0.170 -0.066 -0.020 -0.020 -0.026 -0.024 -0.026 -0.021 -0.065 -0.026 -0.024 -0.026 -0.026 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.026 -0.025 -0.026 -0.025 -0	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084 z-value	0.000 0.000 0.000 p-value 0.802 0.658 0.023 0.001 0.023 0.001 0.023 0.001 0.020 Ratio and Ma p-value 0.005 0.090 0.397 0.001 Sobb Angle p-value 1.000 0.023 0.000 0.121 0.006 0.000 0.000	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50	 1.0 1.0
Au et al., 2013 Variant et al., 2017 Total Heterogeneity: $τ^2 = 0.035$; j Meta-Analysis (Forced E Study Videlaal et al., 2018 Videlaal et al., 2017 Stime et al., 2007 daching et al., 2021 aravira et al., 2021 aravira et al., 2021 Variant et al., 2021 Videlaal et al., 2021 Videlaal et al., 2017 Total Heterogeneity: $τ^2 = 0.045$; Meta-Analysis (Forced E Study Vierband, 2015 Vietton et al., 2021 Vierborde et al., 2025 Viata Vierborde et al., 2013 Vierborde et al., 2015 Vaszay et al., 2017 Total Heterogeneity: $τ^2 = 0$; $χ^2 =$ Meta-Analysis (Total Lu Study Souloussa et al., 2019	$\begin{array}{c} 120\\ 163\\ 1865\\ z^2 = 67.08, \end{array}$	-0,240 -0,401 -0,348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> 0.030 -0,352 -0,420 0.038 -0.277 -0.232 0, df = 5 ($p = 0.0$ y Volume in th <u>Correlation</u> -0.215 -0.128 -0.128 -0.126 -0.128 -0.120 -0.126 -0.128 -0.120 -0.126 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.190 -0.212 -0.183 -0.190 -0.212 -0.183 -0.242 -0.183 -0.242 -0.183 -0.242 -0.190 -0.242 -0.190 -0.212 -0.183 -0.242 -0.190 -0.212 -0.183 -0.242 -0.190 -0.212 -0.183 -0.242 -0.212 -0.183 -0.212 -0.190 -0.212 -0.183 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.212 -0.190 -0.215 -0.190 -0.215 -0.190 -0.215 -0.190 -0.215 -0.190 -0.215 -0.190 -0.215 -0.190 -0.215 -0.190 -0.215 -0.190 -0.190 -0.215 -0.190 -0.190 -0.190 -0.190 -0.190 -0.212 -0.190 -0.193 -0.190 -0.212 -0.190 -0.193 -0.190 -0.212 -0.183 -0.190 -0.212 -0.183 -0.190 -0.212 -0.183 -0.190 -0.212 -0.190 -0.212 -0.193 -0.190 -0.212 -0.183 -0.190 -0.212 -0.183 -0.212 -0.190 -0.212 -0.193 -0.190 -0.212 -0.183 -0.220 -0.240 -0.240 -0.240 -0.2200 -0.2200 -0.2200 -0.2200 -0.2200 -0.2200 -0.2200 -	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.268 -0.271 -0.355 -0.271 -0.268 -0.269 -0.268 -0.268 -0.268 -0.268 -0.241 -0.268 -0.241 -0.268 -0.241 -0.268 -0.241 -0.255 -0.655 -	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.04 -0.04 -0.067 -0.067 -0.067 -0.067 -0.067 -0.067 -0.065 -0.125 -0.051 -0.051 -0.051 -0.055 -0.125 -0.055 -0.125 -0.055 -0.125 -0.055 -0.051 -0.055 -0.055 -0.055 -0.055 -0.057 -0.067 -0.067 -0.067 -0.067 -0.055 -0.0	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value 0.000 -2.277 -4.898 -1.696 0.847 -3.274 -3.274 -2.723 -6.084 z-value -2.084 -2.723 -6.084	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 v Ratio and Mz p-value 1.000 0.005 0.090 0.397 0.001 cobb Angle) p-value 0.006 0.000 0.121 0.006 0.000	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50	 1.0 1.00
Nu et al., 2013 (aszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; feta-Analysis (Forced E Study bid -lat et al., 2018 (kazawa et al., 2011 (aschine et al., 2017 Total Heterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I Study Line et al., 2021 (dePhail., 2015 (bitton et al., 2022) Total Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Pere Study Intered al., 2015 (bitton) (construction) (const	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$ Expiratory Total 73 45 49 139 72 45 49 168 17 45 45 49 22 19.35 Expiratory Total 73 45 49 22 19.35 Expiratory Total 73 45 49 37 45 49 37 45 49 37 49 37 49 37 49 49 37 49 49 49 49 49 22 19.35 Expiratory Total 75 49 40 40 40 40 40 40 40	$\begin{array}{c} -0.240 \\ -0.401 \\ -0.348 \\ 0.0348 \\ 0.0348 \\ 0.0348 \\ 0.0348 \\ 0.0348 \\ 0.030 \\ -0.352 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.420 \\ 0.038 \\ -0.277 \\ -0.462 \\ -0.232 \\ 0.0462 \\ -0.232 \\ 0.0462 \\ -0.232 \\ 0.0462 \\ -0.232 \\ 0.0462 \\ 0.0164 \\ 0.0164 \\ 0.0164 \\ 0.000 \\ -0.128 \\ $	-0.402 -0.523 -0.414 0001); I ² =80.6% le First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% le First Second Lower Limit -0.355 -0.271 -0.408 -0.267 -0.267 -0.268 -0.267 -0.267 -0.266 -0.313 -0.267 -0.354 -0.261 -0.267 -0.410 -0.354 -0.261 -0.267 -0.410 -0.354 -0.241 I ² =0.00%	-0.063 -0.264 -0.243 5 4 and Main Thu Upper Limit 0.258 -0.065 -0.157 0.203 -0.039 -0.198 -0.037 -0.037 d to the Forced <u>Upper Limit</u> -0.066 0.020 0.170 -0.067 Capacity and M Upper Limit 0.268 -0.024 -0.066 -0.170 -0.067 Capacity and M Upper Limit -0.066 -0.125 -0.024 -0.024 -0.024 -0.024 -0.024 -0.025 -0.027 -0.025 -0.027 -0.027 -0.025 -0.027 -0.027 -0.027 -0.025 -0.027	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -3.278 -1.551 -2.723 -6.084 z-value -3.643 -2.593 -2.5	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.002 0.002 0.002 0.005 0.000 0.397 0.001 p-value 1.000 0.023 0.001 0.000 0.397 0.001 0.000 0.121 0.0000 0.0000000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.00000	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50	 1.0 1.00
Nu et al., 2013 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced E Study Vdeflaal et al., 2018 Vacava et al., 2021 Jaching et al., 2021 Jaravira et al., 2021 Jaravira et al., 2017 Total Teterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I Study Lin et al., 2021 VdePhail, 2015 Zeitton et al., 2021 Total Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Pere Study Meta-Analysis (The Pere Study Meta-Analysis (The Pere) Study Meta-Analysis (The Pere) Study Meta-Analysis (The Pere) Study Meta-Analysis (The Pere) Study Meta-Analysis (Total Lu Study Souloussa et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (Total Lu Study Souloussa et al., 2021 Padhyay et al., 1995 Total	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	-0,240 -0,401 -0,348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0,352 -0,420 -0,352 -0,420 -0,232 , df = 5 ($p = 0.1$ y Volume in th <u>Correlation</u> -0,215 -0,128 -0,128 -0,130 -0,166 df = 9 ($p < 0.000$ f the Predicted <u>Correlation</u> -0,193 -0,212 -0,193 -0,193 -0,193 -0,193 -0,193 -0,212 -0,193 -0,193 -0,193 -0,212 -0,193 -0,038 -0,038 -0,038 -0,038 -0,038 -0,038 -0,038 -0,038 -0,038 -0,038 -0,038 -0,047 -0,038 -0,047 -0,037 -0,037 -0,038 -0,047	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.262 -0.408 -0.262 -0.355 -0.271 -0.408 -0.265 -0.313 -0.267 -0.313 -0.267 -0.313 -0.267 -0.314 -0.267 -0.314 -0.267 -0.314 -0.267 -0.314 -0.267 -0.354 -0.267 -0.408 -0.267 -0.267 -0.334 -0.263 -0.282 -0.655 -0.6506 -0.282 -0.655 -0.656 -0.282 -0.655 -0.656 -0.282 -0.282 -0.282 -0.282 -0.282 -0.283 -0.282 -0.283 -0.282	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 -0.037 -0.037 -0.037 -0.037 -0.066 -0.020 -0.020 -0.020 -0.026 -0.024 -0.024 -0.024 -0.025 -0.125 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.0231 -0.0231 -0.0231 -0.097 -0.194 -0.021	-2.648 -5.374 -6.213 pracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084 z-value -3.643 -2.593 -0.379 -2.100	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.023 0.001 0.020 / Ratio and M a p-value 0.005 0.090 0.397 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.121 0.000 0.000 0.121 0.0000 0.0000 0.000 0.00000 0.00000 0.00000 0.000000 0.000000 0.00000000	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI % CI	 1.00 1.00 1.00
Nu et al., 2013 Yatzay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Yata-Analysis (Forced E Study Vdelaal et al., 2018 Vacava et al., 2017 Vacava et al., 2021 Jaching et al., 2021 Jaching et al., 2021 Jaching et al., 2021 Vacava et al., 2017 Total Teterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I Study Lin et al., 2021 VdePhail., 2015 VdePhail., 2015 VdePhail., 2015 VdePhail. et al., 2021 Total Heterogeneity: $\tau^2 = 0.036$; 7 Meta-Analysis (The Per- Study Meta-Analysis (The Per- Study Methail et al., 2015 Newton et al., 2015 Newton et al., 2015 Newton et al., 2015 Newton et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (Total Lu Study Studys et al., 2029 Jpadhyay et al., 1995 Total Heterogeneity: : $\tau^2 = 0.047$;	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 6.7.08, \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ , df = 13 \ (p < 0.1 \\ y \ Volume in th \\ \hline correlation\\ 0.030\\ -0.352\\ -0.420\\ -0.232\\ 0. df = 5 \ (p = 0.1 \\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ 0. df = 5 \ (p = 0.1 \\ 0.038\\ -0.215\\ -0.128\\ -0.128\\ -0.130\\ -0.166\\ df = 9 \ (p < 0.001\\ f \ the Predicted \\ \hline Correlation\\ -0.016\\ 0.000\\ -0.172\\ -0.183\\ 4 \ (p = 0.740); \\ \hline correlation\\ -0.212\\ -0.183\\ 4 \ (p = 0.740); \\ \hline correlation\\ -0.380\\ -0.047\\ -0.330\\ df = 2 \ (p = 0.0380\\ -0.037\\ -0.330\\ df = 2 \ (p = 0.0380\\ -0.037\\ -0.032\\ df = 2 \ (p = 0.0380\\ -0.0380\\ -0.047\\ -0.330\\ -0.047\\ -0.330\\ df = 2 \ (p = 0.0380\\ -0.0380\\ -0.047\\ -0.330\\ -0.047\\ -0.330\\ df = 2 \ (p = 0.0380\\ -0.0380$	-0.402 -0.523 -0.414 0001); I ² =80.6% the First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.627 -0.129 -0.485 -0.663 -0.410 0022); I ² =74.2% the First Second Lower Limit -0.355 -0.271 -0.408 -0.262 -0.271 -0.408 -0.265 -0.267 -0.313 -0.267 -0.354 -0.354 -0.267 -0.314 -0.267 -0.354 -0.267 -0.354 -0.267 -0.314 -0.267 -0.354 -0.267 -0.354 -0.267 -0.314 -0.267 -0.354 -0.267 -0.354 -0.267 -0.410 -0.267 -0.267 -0.267 -0.312 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.267 -0.354 -0.267 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.354 -0.267 -0.267 -0.354 -0.267 -0.282 -0.283 -0.283 -0.278 -0.278 -0.282 -0.358 -0.278 -0.278 -0.282 -0.358 -0.278	-0.063 -0.264 -0.243 -0.243 -0.243 -0.065 -0.157 -0.065 -0.157 -0.037 -0.037 -0.037 -0.037 -0.037 -0.037 -0.037 -0.037 -0.037 -0.037 -0.066 -0.020 -0.170 -0.066 -0.020 -0.170 -0.067 -0.021 -0.057 -0.057 -0	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084 z-value -2.6084	0.000 0.000 0.000 0.000 0.000 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.000 0.000 0.090 0.090 0.090 0.090 0.090 0.090 0.091 0.005 0.090 0.090 0.091 0.005 0.090 0.091 0.000 0.023 0.000 0.023 0.000 0.023 0.000 0.020 0.000 0.020 0.000 0.020 0.000 0.020 0.000 0.020 0.000 0.020 0.000 0.020 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.00000 0.00000000	-1.00 -0.50	ation and 95	 0.50 3% CI 0.50 % CI 0.50 % CI 0.50	
All et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced F Study Webdenat et al., 2018 Vacawa et al., 2018 Vacawa et al., 2021 Jingleman et al., 2021 Jingleman et al., 2021 Jingleman et al., 2021 Meta-Analysis (Forced H Study Methal., 2015 Picture et al., 2022 Total Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Pere Study Iharreborde et al., 2017 Total Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Pere Study Iharreborde et al., 2013 VacPhail et al., 2015 VacPhail et al., 2015 VacPhail et al., 2015 VacPhail et al., 2021 Methar-borde et al., 2013 VacPhail et al., 2015 Vaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (Total Lu Study Souloussa et al., 2019 <u>Section</u> et al., 2025 Jipadhay et al., 1995 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \$	-0.240 -0.401 -0.348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0.352 -0.420 -0.352 -0.420 -0.352 -0.420 -0.232 -0.462 -0.232 -0.462 -0.232 -0.462 -0.232 -0.462 -0.232 -0.462 -0.232 -0.232 -0.462 -0.232 -0.128 -0.128 -0.128 -0.128 -0.128 -0.128 -0.120 -0.128 -0.130 -0.166 -0.193 -0.190 -0.212 -0.183 -0.190 -0.212 -0.183 -0.190 -0.0212 -0.183 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.183 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.193 -0.190 -0.0212 -0.193 -0.020 -0.0212 -0.193 -0.020 -0.0212 -0.030 -0.0212 -0.030 -0.0470 -0.0470 -0.037 -0.0470 -0.0	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.353 -0.241 I Total Lung C Lower Limit -0.354 -0.268 -0.313 -0.268 -0.313 -0.267 -0.410 -0.268 -0.354 -0.224 I Total Capacit	-0.063 -0.264 -0.243 -0.243 -0.243 -0.065 -0.157 -0.065 -0.157 -0.039 -0.198 -0.039 -0.198 -0.037 -0.039 -0.198 -0.037 -0.066 -0.020 -0.020 -0.066 -0.020 -0.020 -0.067 -0.067 -0.067 -0.067 -0.067 -0.067 -0.028 -0.024 -0.024 -0.020 -0.020 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.026 -0.026 -0.020 -0.026 -0.020 -0.026 -0.020 -0.026 -0.020 -0.020 -0.026 -0.020 -0.020 -0.020 -0.020 -0.020 -0.020 -0.020 -0.020 -0.025 -0.020 -0	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value 0.000 -2.277 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.696 0.847 -3.274 -3.274 -3.274 -3.274 -3.274 -3.275 -3.275 -3.278 -3.274 -3.274 -3.274 -3.277 -3.277 -3.277 -3.277 -3.277 -3.277 -3.278 -3.277 -3.277 -3.277 -3.277 -3.277 -3.277 -3.273 -6.084 -3.551 -2.753 -0.379 -2.100 oracic Cobb A	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.020 r Ratio and M 2 p-value 0.005 0.005 0.000 0.397 0.001 p-value 1.000 0.003 0.001 0.001 p-value 1.000 0.003 0.000 0.121 0.006 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000	-1.00 -0.50	ation and 95 ation ation	 0.50 3% CI 0.50 % CI 0.50 % CI 0.50 % CI	
All et al., 2013 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Weta-Analysis (Forced E Study Voldelat et al., 2018 Volzawa et al., 2011 Volzawa et al., 2021 Volzachino et al., 2022 Total Heterogeneity: $\tau^2 = 0.036$; ; Weta-Analysis (Forced I Study Volzachino et al., 2022 Total Heterogeneity: $\tau^2 = 0.036$; ; Weta-Analysis (The Pero Study Volzachi et al., 2015 Volzachi et al., 2015 Vol	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ +0.50\\ 0.034\\ 0.034\\ 0.034\\ 0.034\\ 0.034\\ 0.030\\ -0.352\\ -0.420\\ 0.038\\ -0.277\\ -0.420\\ -0.232\\ 0.0462\\ -0.232\\ 0.0462\\ -0.232\\ 0.0462\\ -0.232\\ 0.0462\\ -0.232\\ 0.0462\\ -0.232\\ 0.0462\\ -0.232\\ 0.0462\\ -0.232\\ 0.036\\ -0.160\\ -0.128\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.160\\ -0.172\\ -0.183\\ 4 (p=0.740);\\ 0.000\\ -0.212\\ -0.193\\ -0.193\\ -0.193\\ -0.193\\ -0.212\\ -0.183\\ 4 (p=0.740);\\ 0.000\\ -0.212\\ -0.193\\ -0.047\\ -0.302\\ df=2 (p=0.038)\\ -0.047\\ -0.0302\\ df=2 (p=0.038)\\ -0.047$	-0.402 -0.523 -0.414 001); I ² =80.6% le First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0022); I ² =74.2% le First Second Lower Limit -0.355 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.271 -0.408 -0.267 -0.267 -0.267 -0.267 -0.267 -0.408 -0.267 -0.271 -0.267 -0.267 -0.267 -0.271 -0.267 -0.267 -0.271 -0.267 -0.267 -0.267 -0.271 -0.267 -0.267 -0.267 -0.267 -0.271 -0.267 -0.267 -0.267 -0.267 -0.267 -0.267 -0.271 -0.267 -0.267 -0.267 -0.267 -0.267 -0.271 -0.267 -0.271 -0.267 -0.271 -0.278 -0.538 -0.	-0.063 -0.264 -0.243 -0.243 -0.243 -0.065 -0.157 0.203 -0.065 -0.157 0.203 -0.039 -0.037 -0.037 -0.066 0.020 0.170 -0.066 0.020 0.170 -0.066 -0.024 -0.067 -0.066 -0.024 -0.170 -0.066 -0.024 -0.170 -0.066 -0.024 -0.024 -0.024 -0.024 -0.024 -0.025 -0.024 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.024 -0.024 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.024 -0.026 -0.026 -0.026 -0.026 -0.026 -0.025 -0.021 -0.0	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -3.278 -1.596 -1.696 -0.847 -3.274 ain Thoracic C z-value -2.805 -1.696 -0.847 -3.274 -3.274 -3.274 -3.274 -3.274 -3.274 -3.275 -1.696 -0.847 -3.273 -6.084 -3.643 -2.593 -3.79 -2.100 oracic Cobb Ai	0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.002 0.002 0.002 0.005 0.000 0.005 0.005 0.000 0.397 0.001 p-value 1.000 0.023 0.001 p-value 1.000 0.005 0.000 0.121 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.000000 0.0000 0.0000 0.00000 0.00000 0.0000 0.00000000	-1.00 -0.50	ation and 95 ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50 % CI 0.50	
Nu et al., 2017 Yeta-Analysis (Forced E Study Vieta-Analysis (Forced E Study Vieta-Analysis (Forced E 1, 2018 Vieta-Analysis (Forced E 1, 2017 Vieta-Analysis (Forced E Study Vieta-Analysis (Forced E Study Vieta-Analysis (Forced E Study Vieta-Analysis (Forced E Study Vieta-Analysis (The Perc Study Vieta-Analysis (Total Lu Study Vieta-Analysis (The Perc Study Vieta-Analysis (The Perc Study Vieta-Analys	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	-0,240 -0,401 -0,348 df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0,352 -0,420 -0,352 -0,420 -0,232 -0,462 -0,232 -0,462 -0,232 -0,462 -0,232 -0,462 -0,232 -0,462 -0,232 -0,462 -0,232 -0,128 -0,128 -0,128 -0,128 -0,128 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,129 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,128 -0,120 -0,020 -0,020 -0,020 -0,030 -0,047 -0,030 -0,047 -0,030 -0,047 -0,030 -0,047 -0,030 -0,047 -0,030 -0,047 -0,010 -0,010 -0,047 -0,030 -0,047 -0,010 -0,010 -0,010 -0,047 -0,047 -0,010 -0	-0.402 -0.523 -0.414 001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.262 -0.408 -0.262 -0.265 -0.338 -0.267 -0.334 -0.267 -0.3410 -0.267 -0.354 -0.267 -0.358 -0.267 -0.313 -0.267 -0.358 -0.267 -0.313 -0.267 -0.358 -0.267 -0.313 -0.267 -0.358 -0.267 -0.313 -0.267 -0.358 -0.267 -0.313 -0.267 -0.358 -0.267 -0.358 -0.267 -0.313 -0.267 -0.358 -0.267 -0.358 -0.267 -0.408 -0.267 -0.410 -0.267 -0.410 -0.267 -0.358 -0.267 -0.410 -0.267 -0.410 -0.267 -0.410 -0.267 -0.358 -0.267 -0.358 -0.267 -0.410 -0.267 -0.410 -0.267 -0.055 -0.648 -0.448 -0	-0.063 -0.264 -0.243 -0.243 -0.243 -0.243 -0.065 -0.157 -0.203 -0.037 -0.037 -0.037 -0.037 -0.037 -0.037 -0.066 -0.020 -0.020 -0.066 -0.020 -0.067 -0.066 -0.020 -0.066 -0.020 -0.020 -0.066 -0.020 -0.021 -0.065 -0.021 -0.051 -0.065 -0.125 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.051 -0.0231 -0.023 -0.125 -0.024 -0.125 -0.024 -0.024 -0.125 -0.051 -0.065 -0.125 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.021 -0.051 -0.023 -0.023 -0.021 -0.021 -0.021 -0.025 -0.025 -0.125 -0.055 -0.125 -0.051 -0.065 -0.125 -0.051 -0.025 -0.021 -0.02	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084 z-value -3.643 -2.593 -0.379 -2.100 oracic Cobb A z-value -1.125 -2.805 -1.125 -2.723 -0.844 -2.593 -0.379 -2.100	0.000 0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.023 0.001 0.020 0.005 0.090 0.397 0.001 i.000 0.033 0.000 0.121 0.000 0.121 0.000 0.121 0.000 0.000 p-value 0.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.035 0.000 0.121 0.000 0.000 0.121 0.000 0.000 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.001 i.000 0.023 0.000 i.000 0.023 0.000 i.000 0.023 0.000 i.000 0.023 0.000 i.000 0.0023 0.000 i.000 0.003 0.000 0.000 0.001 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.000 0.001 0.000 0.001 0.000 0.001 0.025 0.036 0.000 0.001 0.026 0.000 0.001 0.000 0.001 0.0260 0.004	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50 % CI 0.50	
All et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced F Study Webdenat et al., 2018 Vacawa et al., 2018 Vacawa et al., 2021 Jinglman et al., 2021 Jinglman et al., 2021 Jinglman et al., 2021 Meta-Analysis (Forced H Study Methal., 2015 Picture et al., 2021 Metha-Analysis (Forced H Study Methal., 2015 Picture et al., 2022 Total Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Pero Study Uiharreborde et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (The Dero Study Jindreborde et al., 2019 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (The Lu Study Souloussa et al., 2019 Section et al., 2025 Upadhyay et al., 1995 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (The Lu Study Meta-Analysis (The Pero Study Meta-Analysis (The Pero Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study Study	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \$	-0,240 -0,401 -0,348 , df = 13 ($p < 0.1$ y Volume in th <u>Correlation</u> -0,352 -0,420 -0,352 -0,420 -0,232 -0,462 -0,232 -0,128 -0,130 -0,166 -0,212 -0,232	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.261 -0.268 -0.333 -0.261 -0.268 -0.331 -0.268 -0.353 -0.241 I Total Lung C Lower Limit -0.655 -0.606 -0.282 -0.538 -0.538 -0.538 -0.538 -0.578 -0.418 -0.418 -0.437 -0.4	-0.063 -0.264 -0.243 -0.243 -0.243 -0.258 -0.065 -0.157 -0.203 -0.039 -0.198 -0.039 -0.198 -0.037 -0.039 -0.198 -0.037 -0.066 -0.020 -0.067 -0.067 -0.067 -0.067 -0.067 -0.067 -0.067 -0.024 -0.067 -0.024 -0.024 -0.024 -0.025 -0.117 -0.067 -0.025 -0.125 -0.024 -0.024 -0.026 -0.024 -0.026 -0.024 -0.026 -0.020	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.278 -2.319 Vital Capacity z-value 0.000 -2.277 -3.274 -3.275 -3.277 -3.274 -3.274 -3.274 -3.274 -3.274 -3.274 -3.274 -3.274 -3.275 -3.277 -3.274 -3.274 -3.274 -3.274 -3.274 -3.274 -3.277 -3.273 -6.084 -3.279 -3.279 -3.279 -3.279 -3.273 -6.084 -3.279 -3.270 -3.279 -3.270 -3.279 -3.270 -3.279 -3.270 -3.270 -3.279 -3.270	0.000 0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.023 0.001 0.023 0.001 0.023 0.001 0.020 p-value 1.000 0.023 0.001 i i i 0.005 0.090 0.397 0.001 i 0.005 0.090 0.397 0.001 i i 0.005 0.090 0.397 0.001 i i 0.005 0.005 0.000 0.005 0.000 0.005 0.000 0.005 0.000 0.005 0.000 0.000 0.005 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000	-1.00 0.50	ation and 95 ation ation ation 95 ation ation ation ation 95 ation ation ation ation 95 ation ation ation ation 95 ation ation ation 95 ation ation ation 95 ation ation ation ation 95 ation ation ation 95 ation 95 at	 0.50 3% CI 0.50 1% CI 0.50 % CI 0.50 % CI 0.50 % CI 0.50	
Nu et al., 2017 Total Heterogeneity: $r^2 = 0.035$; ; Meta-Analysis (Forced E Study Wodelaal et al., 2018 Value al., 2018 Value al., 2018 Value al., 2021 Sinchard al., 2021 Sinchard al., 2021 Sinchard al., 2021 Study Lin et al., 2021 Study Lin et al., 2021 Study Lin et al., 2021 Study Lin et al., 2021 Study Meta-Analysis (Forced I Study Lin et al., 2025 Study Meta-Analysis (The Perr Study Meta-Analysis (The Perr Study Meta-Analysis (The Second Study Sould et al., 2015 Value al., 2015 Value al., 2027 Stal Meta-Analysis (Total Lu Study Study Souloussa et al., 2017 Study Mutha and Corner, 1985 Total Heterogeneity: $r^2 = 0.047$; Meta-Analysis (The Perc Study Study Souloussa et al., 2017 Study Mutha and Corner, 1985 Total Heterogeneity: $r^2 = 0.047$; Meta-Analysis (The Perc Study	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ , df = 13 \ (p < 0.1 \\ y \ Volume in th \\ \hline correlation\\ 0.030\\ -0.352\\ -0.420\\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ 0. df = 5 \ (p = 0.1 \\ 0.038\\ -0.277\\ -0.462\\ -0.232\\ 0. df = 5 \ (p = 0.1 \\ 0.016\\ -0.215\\ -0.128\\ -0.128\\ -0.130\\ -0.166\\ df = 9 \ (p < 0.00\\ \hline the Predicted \\ \hline correlation\\ -0.212\\ -0.183\\ -0.193\\ -0.193\\ -0.193\\ -0.193\\ -0.193\\ -0.193\\ -0.193\\ -0.380\\ -0.047\\ -0.303\\ -0.061\\ -0.271\\ -0.303\\ -0.300\\ \hline \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% le First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% le First Second Lower Limit -0.355 -0.271 -0.408 -0.267 -0.271 -0.408 -0.267 -0.285 li Total Lung C Lower Limit -0.267 -0.271 -0.268 -0.271 -0.267 -0.267 -0.267 -0.267 -0.267 -0.271 -0.268 -0.267 -0.263 -0.267 -0.264 -0.267 -0.635 -0.635 -0.6418 -0.282 -0.538 -0.578 -0.504 -0.578 -0.502 -0.514 -0.418 -0.	-0.063 -0.264 -0.243 -0.243 -0.243 -0.243 -0.065 -0.157 0.203 -0.039 -0.037 -0.037 -0.037 -0.037 -0.066 0.020 0.170 -0.066 0.020 0.170 -0.066 -0.024 -0.066 -0.024 -0.065 -0.024 -0.065 -0.024 -0.024 -0.065 -0.024 -0.065 -0.024 -0.066 -0.020 -0.065 -0.024 -0.066 -0.020 -0.067 -0.060 -0.021 -0.023 -0.028 -0.	-2.648 -5.374 -6.213 oracic Cobb Ai z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -0.847 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084 z-value -2.643 -2.579 -2.100 oracic Cobb A z-value -2.805 -1.696 -0.847 -3.274 -3.274 -3.274 -3.274 -3.274 -3.275 -0.847 -3.273 -6.084 -2.551 -2.753 -0.379 -2.100 oracic Cobb A	0.000 0.000 0.000 ngle) p-value 0.802 0.017 0.002 0.658 0.002 0.002 0.002 0.002 0.005 0.005 0.005 0.005 0.005 0.005 0.005 0.005 0.005 0.397 0.001 2005 Angle) p-value 1.000 0.023 0.000 0.121 0.006 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0	-1.00 -0.50	ation and 95 ation ation ation 95 ation ation ation ation 95 ation ation 95 ation ation 95 ation ation ation 95 ation ation 95 ation ation 95 ation ation 95 ation ation 95 ation 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50 % CI 0.50	
All et al., 2017 Total Heterogeneity: $r^2 = 0.035$; ; Meta-Analysis (Forced E Study Webdaal et al., 2018 (Kazawa et al., 2017) Study: 2007 Machino et al., 2021 Jaravira et al., 2021 Jaravira et al., 2021 Jaravira et al., 2021 Grant al., 2017 Total Heterogeneity: : $\tau^2 = 0.045$; Meta-Analysis (Forced I Study Lin et al., 2021 McPhail, 2015 Diction et al., 2022 Total Heterogeneity: $\tau^2 = 0.036$; ; Meta-Analysis (The Percent Study Mitarrebord et al., 2013 McPhail et al., 2015 Meta-Analysis (The Percent al., 2015 Meta-Analysis (Total Lu Study Mitarebord et al., 2015 Vaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (Total Lu Study Murbande et al., 2017 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (Total Lu Study Murbanda and Corner, 1985 Talahashi et al., 2007 Dyadrhay et al., 1995 Fotal Heterogeneity: : $\tau^2 = 0.047$; Meta-Analysis (The Perc Study Murband and Corner, 1985 Talahashi et al., 2017 Total Heterogeneity: : $\tau^2 = 0.047$; Meta-Analysis (The Perc Study Murband and Corner, 1985 Talahashi et al., 2017 Total Heterogeneity: : $\tau^2 = 0.047$; Meta-Analysis (The Perc Study Murband and Corner, 1985 Talahashi et al., 2017 Total	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \end{array}$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ , df = 13 \ (p < 0.1 \\ \hline \\ \ \\ \ \\ \ \\ \ \\ \ \\ \ \\ \ \\ \ \\ \$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0022); I ² =74.2% be First Second Lower Limit -0.266 -0.354 -0.271 -0.408 -0.262 -0.271 -0.408 -0.265 -0.354 -0.267 -0.410 -0.271 -0.408 -0.266 -0.354 -0.267 -0.410 -0.268 -0.351 -0.268 -0.354 -0.267 -0.410 -0.268 -0.313 -0.267 -0.410 -0.354 -0.267 -0.410 -0.268 -0.313 -0.267 -0.410 -0.268 -0.351 -0.264 -0.353 -0.255 -0.655 -	-0.063 -0.264 -0.243 -0.243 -0.243 -0.243 -0.065 -0.157 -0.203 -0.039 -0.198 -0.037 -0.039 -0.198 -0.037 -0.039 -0.198 -0.037 -0.066 -0.020 -0.066 -0.020 -0.066 -0.020 -0.067 -0.066 -0.020 -0.020 -0.026 -0.024 -0.026 -0.026 -0.026 -0.125 b Angle) Upper Limit -0.065 -0.021 -0.065 -0.125 -0.021 -0.025 -0.125 -0.021 -0.021 -0.021 -0.021 -0.021 -0.025 -0.125 -0.021 -0.025 -0.021 -0.021 -0.025 -0.021 -0.02	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -0.443 -2.275 -3.278 -2.319 Vital Capacity z-value -2.805 -1.696 -1.696 -2.805 -1.696 -3.274 ain Thoracic C z-value 0.000 -2.277 -4.898 -1.551 -2.723 -6.084 z-value -3.643 -2.593 -0.379 -2.100 oracic Cobb A z-value -1.125 -2.862 -2.862 -2.862 -2.862 -2.862 -2.561 -3.348 -5.136	0.000 0.000 0.000 0.000 p-value 0.802 0.658 0.023 0.001 0.023 0.001 0.023 0.001 0.020 revalue 0.005 0.090 0.397 0.001 i.000 0.023 0.001 i.000 0.23 0.001 i.000 0.121 0.000 0.000 0.121 0.000 0.000 0.000 i.121 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.00000 0.000000 0.00000000	-1.00 -0.50	ation and 95	 0.50 % CI 0.50 % CI 0.50 % CI 0.50 % CI 0.50	
All et al., 2017 Total Heterogeneity: $\tau^2 = 0.035$; ; Meta-Analysis (Forced F Study Meta-Analysis (Forced F Study Modelait et al., 2018 Kazawa et al., 2021 Singleman et al., 2021 Saravira et al., 2021 Saravira et al., 2021 Saravira et al., 2021 Meta-Analysis (Forced F Study Methail., 2015 Pietton et al., 2021 Methail., 2015 Pietton et al., 2021 Methail., 2015 Pietton et al., 2021 Methail., 2015 Pietton et al., 2021 Methail., 2015 Pietton et al., 2025 Yaszay et al., 2017 Total Heterogeneity: $\tau^2 = 0$, $\chi^2 =$ Meta-Analysis (The Pero Study Bouloussa et al., 2019 Dyadhyay et al., 1995 Total Heterogeneity: $\tau^2 = 0$; $\chi^2 =$ Meta-Analysis (The Lu Study Bouloussa et al., 2019 Discuton et al., 2025 Upadhyay et al., 1995 Total Heterogeneity: $\tau^2 = 0$, $\chi^2 =$ Meta-Analysis (The Pero Study Mirhead and Corner, 1985 Total Heterogeneity: $\tau^2 = 0$, $\chi^2 = 0$; $\chi^$	$\begin{array}{c} 120\\ 163\\ 1865\\ \chi^2 = 67.08, \\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \$	$\begin{array}{c} -0.240\\ -0.401\\ -0.348\\ , df = 13 \ (p < 0.1 \\ v \ Volume in th \\ \hline Correlation\\ 0.030\\ -0.352\\ -0.420\\ 0.038\\ -0.277\\ -0.420\\ -0.232\\ 0. df = 5 \ (p = 0.4 \\ v \ Volume in th \\ \hline Correlation\\ -0.215\\ -0.128\\ -0.130\\ -0.166\\ df = 9 \ (p < 0.00\\ -0.172\\ -0.130\\ -0.166\\ df = 9 \ (p < 0.00\\ -0.172\\ -0.130\\ -0.166\\ df = 9 \ (p < 0.00\\ -0.172\\ -0.133\\ 4 \ (p = 0.740); \\ \vdots \\ the Predicted \\ \hline Correlation\\ -0.047\\ -0.380\\ -0.047\\ -0.380\\ -0.047\\ -0.380\\ -0.047\\ -0.302\\ df = 2 \ (p = 0.03\\ fthe Predicted \\ \hline Correlation\\ -0.047\\ -0.302\\ df = 2 \ (p = 0.03\\ fthe Predicted \\ \hline Correlation\\ -0.047\\ -0.302\\ df = 2 \ (p = 0.03\\ df = 0.272\\ -0.272\\ 3 \ (p = 0.840); 1 \\ \end{array}$	-0.402 -0.523 -0.414 0001); I ² =80.6% are First Second Lower Limit -0.201 -0.585 -0.627 -0.129 -0.485 -0.663 -0.410 0002); I ² =74.2% be First Second Lower Limit -0.355 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.271 -0.408 -0.268 -0.268 -0.268 -0.333 -0.267 -0.408 -0.268 -0.353 -0.271 -0.408 -0.268 -0.313 -0.268 -0.353 -0.261 -0.354 -0.268 -0.353 -0.241 I ² =0.00%	-0.063 -0.264 -0.243 -0.243 -0.243 -0.243 -0.258 -0.258 -0.065 -0.157 0.203 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.039 -0.04 -0.067 -0.066 -0.020 0.020 0.020 -0.067 -0.067 -0.067 -0.067 -0.067 -0.067 -0.024 -0.067 -0.024 -0.024 -0.024 -0.024 -0.024 -0.051 -0.065 -0.125 -0.023 -0.125 -0.024 -0.024 -0.024 -0.051 -0.065 -0.125 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.025 -0.125 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.024 -0.025 -0.025 -0.025 -0.025 -0.024 -0.024 -0.025 -0.024 -0.024 -0.025 -0.025 -0.025 -0.024 -0.025 -0.025 -0.025 -0.024 -0.025 -0.025 -0.025 -0.025 -0.024 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.025 -0.027 -0.027 -0.067 -0.025 -0.027 -0.027 -0.027 -0.021 -0.023 -0.028 -0.021 -0.021 -0.021 -0.028 -0.021 -0.028 -0.021 -0.028 -0.021 -0.028 -0.021 -0.028 -0	-2.648 -5.374 -6.213 oracic Cobb A: z-value 0.251 -2.383 -3.036 0.443 -2.275 -3.278 -3.274 -3.274 -3.274 -3.274 -3.275 -2.805 -1.696 -3.277 -3.273 -6.084 -3.551 -2.723 -6.084 -3.551 -2.723 -6.084 -3.543 -3.279 -2.100 oracic Cobb A z-8.62 -3.348 -5.136	0.000 0.000 0.000 0.000 p-value 0.802 0.017 0.002 0.658 0.002 0.023 0.001 0.023 0.001 0.020 / Ratio and M 2 p-value 0.005 0.090 0.397 0.001 0.005 0.090 0.397 0.001 0.001 0.003 0.001 0.000 0.000 0.121 0.0000 0.000 0.00000 0.00000 0.00000 0.00000 0.00000000	-1.00 -0.50	ation and 95 ation ation ation 95 ation ation ationation ation ation ation ation ation ation ation ation ation ati	 0.50 % CI 0.50 % CI 0.50 % CI 0.50 % CI 0.50	

Meta-Analysis for Multiple Regression Model (The Percentage of the Predicted Forced Vital Capacity and Main Thoracic Cobb Angle)										
Study	Total	Correlation	Lower Limit	Upper Limit	z-value	p-value	<u>C</u>	orrelation a	and 95% CI	
Newton et al., 2005	631	-0.190	-0.264	-0.113	-4.812	0.000	- I	1 = 1	1	
Tung et al., 2018	142	-0.530	-0.639	-0.400	-6.958	0.000	-	₄ ─		
Wang et al., 2019	72	-0.805	-0.874	-0.705	-9.242	0.000		1 1		
Xu et al., 2015	120	-0.210	-0.375	-0.032	-2.304	0.021				
Total	965	-0.309	-0.365	-0.250	-9.858	0.000		🔶		
Heterogeneity: : $\tau^2 = 0.124$; $\gamma^2 = 65.12$, df = 3 ($p < 0.001$); I ² = 95.40%								0.50 0.0	0 0.50	1.00
		-								
Meta-Analysis for Multip	ole Regre	ession Model (The Percentage	e of Predicted F	orced Vital C	apacity and Th	oracic kyph	osis angle)	
Study	Total	Correlation	Lower Limit	Upper Limit	z-value	p-value	C	orrelation a	and 95% CI	
McPhail et al., 2015	169	0.280	0.135	0.413	3.707	0.000				
Newton et al., 2005	631	0.207	0.131	0.281	5.273	0.001				
Tung et al., 2018	142	0.310	0.153	0.452	3.779	0.000				
Yaszay et al., 2017	163	0.263	0.114	0.400	3.402	0.001				
Yu et al., 2017	166	0.127	-0.026	0.274	1.624	0.104		1 1	┝═╌	
Total	1271	0.226	0.172	0.277	8.133	0.000		1 1	♦	I
Heterogeneity: $\tau^2 = 0$: $\gamma^2 = 3$	90 $df =$	4(n = 0.420):	$I^2 = 0.00\%$				-1.00	-0.50 0.0	00 0.50	1.00

Heterogeneity: $\tau^2 = 0$; $\chi^2 = 3.90$, df = 4 (p = 0.420); I² = 0.00%

Meta-Analysis for Multiple Regression Model (The Percentage of the Predicted Forced Expiratory Volume in the First One Second and Main Thoracic Kynhosis)

Study	Total	Correlation	Lower Limit	Upper Limit	z-value	p-value		Correlat	ion and	<u>95% CI</u>	
McPhail et al., 2015	169	0.210	0.061	0.350	2.747	0.006	1	1	1	– 1	1
Newton et al., 2005	631	0.203	0.126	0.276	5.146	0.000					
Yu et al., 2017	166	0.730	0.650	0.794	11.860	0.000			-	- -	•
Total (95% CI)	966	0.318	0.260	0.374	10.207	0.000				◆	
Heterogeneity: $\tau^2 = 0.140$; χ^2	$^{2} = 70.50$	df = 2 (p < 0.0)	1001); $I^2 = 97.16\%$	6			-1.00	-0.50	0.00	0.50	1.00

Fig. 3 Forest plots of multivariate meta-analysis

may contribute to such findings [8]. Given the high prevalence of irreversible obstructive lung diseases in patients with moderate to severe AIS, endoscopy or chest imaging may be indicated for this airway obstruction [16].

The consistent findings of significant but weak correlations between various structural characteristics and pulmonary function may be ascribed to no adjustment for confounders (e.g., BMI and duration of bracing). Abnormal mechanical loading of respiratory muscles and altered muscle length-tension relationship can affect respiratory muscle contraction and lung function [7, 63], especially in patients with mild AIS [60]. Higher BMI is associated with better %FVC in teenagers with Cobb angle > 40° [38, 42]. Research found that the association between BMI and %FVC was stronger than those between thoracic Cobb angles or kyphosis angles and %FVC [38]. Heavier teens tend to have greater thoracic kyphosis, which yields better %FVC than hypokyphotic peers [38]. Additionally, one study found that brace wearing temporarily compromised %FEV₁ in AIS patients after accounting for thoracic kyphosis [51], although it was unclear whether participants took off the brace during spirometry. Compared to AIS patients without bracing, patients with a thoracic curve and bracing displayed significantly poorer %FVC and %FEV₁ [44, 51]. However, the pulmonary function/compliance restores to previous conditions once the brace is removed [64]. Likewise, the negative association between lumbar lordosis and %FVC or %FEV $_1$ might have disappeared if confounders were considered.

This review had some limitations. Because many included studies performed pulmonary function tests on AIS patients

preoperatively, their findings may represent patients with more severe curves. Further, most included studies did not define the vertebral levels for classifying the proximal and main thoracic curves, which might introduce discrepancies in our pooled results.

Implications

Most included studies measured anteroposterior and lateral spinal features on radiographs. Future studies should adopt low-dose biplanar X-ray imaging for three-dimensional thoracic cage and spinal structure reconstruction [19], which could capture the three-dimensional impacts of spinal/thoracic deformities on patients with AIS. This allows comprehensive evaluation of the relations between spinal deformities and lung function, which may guide clinical management and research.

While patients with mild AIS may not show respiratory dysfunction at rest, they may display reduced functional capacity [65], or maximum oxygen uptake during exercise tolerance tests [50]. Spirometry may not detect subtle deterioration or dyspnea on exertion, which may indicate scoliosis-related respiratory decline. Clinicians should conduct progressive exercise tests on patients with suspected respiratory impairments to detect early respiratory dysfunction. If the curve progresses, regular progressive exercise tests are recommended [57].

Scoliosis can directly (spinal deformity) or indirectly (respiratory muscle weakness/ inefficiency) affect respiratory function. Although patients with mild-to-moderate scoliosis may not experience dramatic pulmonary impairments during daily activities, it is important to use bracing or physiotherapy scoliosis-specific exercises to prevent or delay curve progression in these patients [64]. However, bracing should be worn for at least 16 h per day to prevent curve progression [57, 66]. Therefore, aerobic training should be prescribed to patients with bracing to optimize their lung functions.

Since pulmonary deficits in AIS patients may worsen with curve progression, patients indicated for surgical correction may experience pulmonary impairment secondary to severe scoliosis [67]. While AIS patients with moderate lung volume are less likely to require postoperative ventilatory support [37], those with moderate or severe defects (<60% of predicted VC) may indicate high-risk surgical fusion. The latter should undergo full spirometry before surgery. VC can be used as a screening indicator for all patients before spinal surgery [37] because such surgery may adversely affect pulmonary function/compliance [68].

Because there was no included prospective study, the causal relations between changes in spinal/thoracic deformity and changes in lung function remain unclear. Future prospective studies should investigate such relations after adjusting for confounders. Further, as prior research involving AIS patients aged > 18 years revealed that patients had worsening pulmonary function (e.g., FVC) as they aged [67, 69], future prospective research with long-term follow-ups should determine whether AIS patients with near-normal, mild, or moderate lung dysfunction would experience declined lung function and body's functionality in later life [70].

Conclusions

This systematic review highlights that larger proximal and main thoracic Cobb angles, smaller kyphosis angles, greater lumbar lordotic angles, a longer thoracic curve, a larger rib hump, increased apical vertebral rotation angles and smaller rib cages are associated with poorer pulmonary functions. Other factors can also affect the lung function in these patients. Nevertheless, the clinical impact of scoliosis on lung function is mainly subclinical except for those with severe structural deformity. We definitely need more research to strengthen the quality of evidence. Future prospective studies should evaluate the temporal relations between changes in spinal/thoracic parameters and changes in pulmonary function in order to inform the clinical management of AIS patients with potential respiratory decline.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00586-022-07371-z.

Acknowledgements The authors would like to thank Ms. Rebeca Chan, Mr. Johnny Yan, Ms. Rachel Yan, and Mr. Kenney Lau for their help in the search or assisting the data analyses.

Funding Prof. Stefano Negrini is holding stocks of Italian Scientific Spine Institute. No funding was received for conducting this study.

Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interests There were no financial or competing conflicts of interest in relation to this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Soucacos PN, Zacharis K, Soultanis K, Gelalis J, Xenakis T, Beris AE (2000) Risk factors for idiopathic scoliosis: review of a 6-year prospective study. Orthopedics 23:833–838
- Konieczny MR, Senyurt H, Krauspe R (2013) Epidemiology of adolescent idiopathic scoliosis. J Child Orthop 7:3–9. https://doi. org/10.1007/s11832-012-0457-4
- Wajchenberg M, Astur N, Kanas M, Martins DE (2016) Adolescent idiopathic scoliosis: current concepts on neurological and muscular etiologies. Scoli Spinal Disord 11:1–5
- 4. Wong AY, Samartzis D, Cheung PW, Cheung JPY (2019) How common is back pain and what biopsychosocial factors are associated with back pain in patients with adolescent idiopathic scoliosis? Clin Orthop Relat Res 477:676
- Misterska E, Glowacki M, Latuszewska J, Adamczyk K (2013) Perception of stress level, trunk appearance, body function and mental health in females with adolescent idiopathic scoliosis treated conservatively: a longitudinal analysis. Qual Life Res 22:1633–1645. https://doi.org/10.1007/s11136-012-0316-2
- Sperandio EF, Alexandre AS, Liu CY, Poletto PR, Gotfryd AO, Vidotto MC, Dourado VZ (2014) Functional aerobic exercise capacity limitation in adolescent idiopathic scoliosis. Spine J 14:2366–2372
- Abdelaal AAM, Abd El Kafy EMAES, Elayat MSEM, Sabbahi M, Badghish MSS (2018) Changes in pulmonary function and functional capacity in adolescents with mild idiopathic scoliosis: observational cohort study. J Int Med Res 46:381–391
- Kim YJ, Lenke LG, Bridwell KH, Cheh G, Whorton J, Sides B (2007) Prospective pulmonary function comparison following posterior segmental spinal instrumentation and fusion of adolescent idiopathic scoliosis: Is there a relationship between major thoracic curve correction and pulmonary function test improvement? Spine 32:2685–2693. https://doi.org/10.1097/BRS.0b013 e31815a7b17
- Newton PO, Faro FD, Gollogly S, Betz RR, Lenke LG, Lowe TG (2005) Results of preoperative pulmonary function testing of

adolescents with idiopathic scoliosis: a study of six hundred and thirty-one patients. JBJS 87:1937–1946

- Banjar HH (2003) Pediatric scoliosis and the lung. Saudi Med J 24:957–963
- Takahashi S, Suzuki N, Asazuma T, Kono K, Ono T, Toyama Y (2007) Factors of thoracic cage deformity that affect pulmonary function in adolescent idiopathic thoracic scoliosis. Spine 32:106–112
- Wood KB, Schendel MJ, Dekutoski MB, Boachie-Adjei O, Heithoff KH (1996) Thoracic volume changes in scoliosis surgery. Spine 21:718–723
- Kearon C, Killian J (1993) Fadors determining pulmonary fundion in adolescent idiopathic thoracic scoliosis. Am Rev Respir Dis 148:288–294
- Wozniczka JK, Ledonio CG, Polly DW, Rosenstein BE, Nuckley DJ (2017) Adolescent idiopathic scoliosis thoracic volume modeling: the effect of surgical correction. J Pediatr Orthop 37:e512-e518
- Leong J, Lu W, Luk K, Karlberg E (1999) Kinematics of the chest cage and spine during breathing in healthy individuals and in patients with adolescent idiopathic scoliosis. Spine 24:1310
- McPhail GL, Ehsan Z, Howells SA, Boesch RP, Fenchel MC, Szczesniak R, Jain V, Agabegi S, Sturm P, Wall E (2015) Obstructive lung disease in children with idiopathic scoliosis. J Pediatr 166:1018–1021
- Ilharreborde B, Dubousset J, Skalli W, Mazda K (2013) Spinal penetration index assessment in adolescent idiopathic scoliosis using EOS low-dose biplanar stereoradiography. Eur Spine J 22:2438–2444. https://doi.org/10.1007/s00586-013-2892-4
- Kempen DHR, Heemskerk JL, Kaçmaz G, Altena MC, Reesink HJ, Vanhommerig JW, Willigenburg NW (2022) Pulmonary function in children and adolescents with untreated idiopathic scoliosis: a systematic review with meta-regression analysis. Spine J. https://doi.org/10.1016/j.spinee.2021.12.011
- Melhem E, Assi A, El Rachkidi R, Ghanem I (2016) EOS® biplanar X-ray imaging: concept, developments, benefits, and limitations. J Child Orthop 10:1–14
- 20. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336–341
- Altaf F, Gibson A, Dannawi Z, Noordeen H (2013) Adolescent idiopathic scoliosis. Bmj 346
- Ovadia D (2013) Classification of adolescent idiopathic scoliosis (AIS). J Child Orthop 7:25–28. https://doi.org/10.1007/ s11832-012-0459-2
- Bunnell WP (1984) An objective criterion for scoliosis screening. J Bone Joint Surg 66:1381–1387. https://doi.org/10.2106/00004 623-198466090-00010
- Dubousset J, Wicart P, Pomero V, Barois A, Estournet B (2003) Spinal penetration index: new three-dimensional quantified reference for lordoscoliosis and other spinal deformities. J Orthop Sci 8:41–49. https://doi.org/10.1007/s007760300007
- Ito K, Kawakami N, Miyasaka K, Tsuji T, Ohara T, Nohara A (2012) Scoliosis associated with airflow obstruction due to endothoracic vertebral hump. Spine (Phila Pa 1976) 37:2094–2098. https://doi.org/10.1097/BRS.0b013e31825d2ea3
- Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158:280–286
- Downes MJ, Brennan ML, Williams HC, Dean RS (2016) Development of a critical appraisal tool to assess the quality of crosssectional studies (AXIS). BMJ Open 6:e011458
- Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.

- 29. Portney LG (2015) Foundations of clinical research : applications to practice. Philadelphia, PA : F.A. Davis Company, Philadelphia, PA
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed) 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
- 31. Wong AYL, Chan LLY, Lo CWT, Chan WWY, Lam KCK, Bao JCH, Ferreira ML, Armijo-Olivo S (2021) Prevalence/incidence of low back pain and associated risk factors among nursing and medical students: a systematic review and meta-analysis. PM & R 13:1266–1280. https://doi.org/10.1002/pmrj.12560
- 32. Lau KKL, Samartzis D, To NSC, Harada GK, An HS, Wong AYL (2021) Demographic, surgical, and radiographic risk factors for symptomatic adjacent segment disease after lumbar fusion: a systematic review and meta-analysis. J Bone Joint Surg 103:1438– 1450. https://doi.org/10.2106/JBJS.20.00408
- Bouloussa H, Pietton R, Vergari C, Haen TX, Skalli W, Vialle R (2019) Biplanar stereoradiography predicts pulmonary function tests in adolescent idiopathic scoliosis: a cross-sectional study. Eur Spine J 28:1962–1969. https://doi.org/10.1007/ s00586-019-05940-3
- Huh S, Eun LY, Kim NK, Jung JW, Choi JY, Kim HS (2015) Cardiopulmonary function and scoliosis severity in idiopathic scoliosis children. Korean J Pediatr 58:218
- Lin Y, Feng E, Shen J, Tan H, Jiao Y, Rong T, Chen L, Yuan W, Cong H, Liu S, Luo J (2022) Influences of thoracic spinal deformity on exercise performance and pulmonary function: a prospective study of 168 patients with adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 47:107–115. https://doi.org/10.1097/brs. 0000000000004161
- Machino M, Kawakami N, Ohara T, Saito T, Tauchi R, Imagama S (2021) Three-dimensional reconstruction image by biplanar stereoradiography reflects pulmonary functional states in adolescent idiopathic scoliosis. J Clin Neurosci 88:178–184. https://doi.org/ 10.1016/j.jocn.2021.03.043
- 37. Muirhead A, Conner AN (1985) The assessment of lung function in children with scoliosis. J Bone Joint Surg Br 67:699–702
- Tung R, Uvodich M, Anderson JT, Carpenter K, Sherman A, Lozano R (2018) Do heavier patients with adolescent idiopathic scoliosis have more preserved thoracic kyphosis and pulmonary function? Spine Deform 6:704–706
- Upadhyay SS, Mullaji AB, Luk KD, Leong JC (1995) Relation of spinal and thoracic cage deformities and their flexibilities with altered pulmonary functions in adolescent idiopathic scoliosis. Spine 20:2415–2420. https://doi.org/10.1097/00007632-19951 1001-00008
- Villamor GA, Andras LM, Redding G, Chan P, Yang J, Skaggs DL (2019) A comparison of maximal voluntary ventilation and forced vital capacity in adolescent idiopathic scoliosis patients. Spine Deform 7:729–733. https://doi.org/10.1016/j.jspd.2019.02. 007
- 41. Wang Y, Yang F, Wang D, Zhao H, Ma Z, Ma P, Hu X, Wang S, Kang X, Gao B (2019) Correlation analysis between the pulmonary function test and the radiological parameters of the main right thoracic curve in adolescent idiopathic scoliosis. J Orthop Surg Res 14:443. https://doi.org/10.1186/s13018-019-1451-z
- 42. Xu L, Sun X, Zhu Z, Qiao J, Mao S, Qiu Y (2015) Body mass index as an indicator of pulmonary dysfunction in patients with adolescent idiopathic scoliosis. J Spinal Disord Tech 28:226–231. https://doi.org/10.1097/BSD.0b013e31825d97df
- 43. Yaszay B, Bastrom TP, Bartley CE, Parent S, Newton PO (2017) The effects of the three-dimensional deformity of adolescent idiopathic scoliosis on pulmonary function. Eur Spine J 26:1658–1664
- 44. Yu B, Wang Y, Qiu G, Shen J, Zhang J, Lao L (2013) The influence of preoperative brace treatment on the pulmonary function

test in female adolescent idiopathic scoliosis. J Spinal Disord Tech 26:E254–E258. https://doi.org/10.1097/BSD.0b013e318289be35

- 45. Akazawa T, Kotani T, Sakuma T, Nakayama K, Iijima Y, Torii Y, Iinuma M, Kuroya S, Asano K, Ueno J, Yoshida A, Murakami K, Minami S, Orita S, Inage K, Shiga Y, Nakamura J, Inoue G, Miyagi M, Saito W, Eguchi Y, Fujimoto K, Takahashi H, Ohtori S, Niki H (2021) Pulmonary function improves in patients with adolescent idiopathic scoliosis who undergo posterior spinal fusion regardless of thoracoplasty: a mid-term follow-up. Spine Surg Relat Res 5:22–27. https://doi.org/10.22603/SSRR.2020-0077
- Daruwalla J, Tan W (1985) Spirometric pulmonary function tests before and after surgical correction of idiopathic scoliosis in adolescents. Ann Acad Med Singapore 14:475–478
- 47. Gitelman Y, Lenke LG, Bridwell KH, Auerbach JD, Sides BA (2011) Pulmonary function in adolescent idiopathic scoliosis relative to the surgical procedure: a 10-year follow-up analysis. Spine (Phila Pa 1976) 36:1665–1672. https://doi.org/10.1097/ BRS.0b013e31821bcf4c
- Kim YJ, Lenke LG, Bridwell KH, Kim KL, Steger-May K (2005) Pulmonary function in adolescent idiopathic scoliosis relative to the surgical procedure. J Bone Joint Surg Am 87:1534–1541. https://doi.org/10.2106/JBJS.C.00978
- Pietton R, Bouloussa H, Langlais T, Taytard J, Beydon N, Skalli W, Vergari C, Vialle R (2022) Estimating pulmonary function after surgery for adolescent idiopathic scoliosis using biplanar radiographs of the chest with 3D reconstruction. Bone Joint J 104-b:112–119. https://doi.org/10.1302/0301-620x.104b1.Bjj-2021-0337.R2
- Barrios C, Pérez-Encinas C, Maruenda JI, Laguía M (2005) Significant ventilatory functional restriction in adolescents with mild or moderate scoliosis during maximal exercise tolerance test. Spine 30:1610–1615. https://doi.org/10.1097/01.brs.0000169447. 55556.01
- Ran B, Fan Y, Yuan F, Guo K, Zhu X (2016) Pulmonary function changes and its influencing factors after preoperative brace treatment in patients with adolescent idiopathic scoliosis: a retrospective case-control study. Medicine 95:e5088. https://doi.org/ 10.1097/MD.00000000005088
- Saraiva BMA, Araujo GS, Sperandio EF, Gotfryd AO, Dourado VZ, Vidotto MC (2018) Impact of scoliosis severity on functional capacity in patients with adolescent idiopathic scoliosis. Pediatr Exerc Sci 30:243–250. https://doi.org/10.1123/pes.2017-0080
- 53. Szeinberg A, Canny GJ, Rashed N, Veneruso G, Levison H (1988) Forced vital capacity and maximal respiratory pressures in patients with mild and moderate scoliosis. Pediatr Pulmonol 4:8–12
- 54. Murray JF, Nadel JA (2000) Textbook of respiratory medicine. Saunders, Philadelphia
- 55. Machino M, Kawakami N, Ohara T, Saito T, Tauchi R, Imagama S (2020) Accuracy of rib cage parameters from 3-Dimensional reconstruction images obtained using simultaneous biplanar radiographic scanning technique in adolescent idiopathic scoliosis: Comparison with conventional computed tomography. J Clin Neurosci 75:94–98. https://doi.org/10.1016/j.jocn.2020.03.016
- Upadhyay S, Mullaji A, Luk K, Leong J (1995) Evaluation of deformities and pulmonary function in adolescent idiopathic right thoracic scoliosis. Eur Spine J 4:274–279

- Koumbourlis AC (2006) Scoliosis and the respiratory system. Paediatr Respir Rev 7:152–160
- 58. Vitale MG, Matsumoto H, Bye MR, Gomez JA, Booker WA, Hyman JE, Roye DP Jr (2008) A retrospective cohort study of pulmonary function, radiographic measures, and quality of life in children with congenital scoliosis: an evaluation of patient outcomes after early spinal fusion. Spine 33:1242–1249
- 59. Thilagaratnam S (2007) School-based screening for scoliosis: is it cost-effective? Singapore Med J 48:1012–1017
- Smyth R, Chapman K, Wright T, Crawford J, Rebuck A (1984) Pulmonary function in adolescents with mild idiopathic scoliosis. Thorax 39:901–904
- Cooper DM, Rojas JV, Mellins RB, Keim HA, Mansell AL (1984) Respiratory mechanics in adolescents with idiopathic scoliosis. Am Rev Respir Dis 130:16–22
- Weinstein SL (2019) The natural history of adolescent idiopathic scoliosis. J Pediatr Orthop 39:S44–S46. https://doi.org/10.1097/ BPO.000000000001350
- Martínez-Llorens J, Ramírez M, Colomina M, Bagó J, Molina A, Cáceres E, Gea J (2010) Muscle dysfunction and exercise limitation in adolescent idiopathic scoliosis. Eur Respir J 36:393–400
- Katsaris G, Loukos A, Valavanis J, Vassiliou M, Behrakis P (1999) The immediate effect of a Boston brace on lung volumes and pulmonary compliance in mild adolescent idiopathic scoliosis. Eur Spine J 8:2–7
- 65. Duiverman M, de Boer E, van Eykern L, de Greef M, Jansen D, Wempe J, Kerstjens H, Wijkstra P (2009) Respiratory muscle activity and dyspnea during exercise in chronic obstructive pulmonary disease. Respir Physiol Neurobiol 167:195–200
- 66. Roye BD, Simhon ME, Matsumoto H, Bakarania P, Berdishevsky H, Dolan LA, Grimes K, Grivas TB, Hresko MT, Karol LA, Lonner BS, Mendelow M, Negrini S, Newton PO, Parent EC, Rigo M, Strikeleather L, Tunney J, Weinstein SL, Wood G, Vitale MG (2020) Establishing consensus on the best practice guidelines for the use of bracing in adolescent idiopathic scoliosis. Spine Deform 8:597–604. https://doi.org/10.1007/s43390-020-00060-1
- 67. Johari J, Sharifudin MA, Ab Rahman A, Omar AS, Abdullah AT, Nor S, Lam WC, Yusof MI (2016) Relationship between pulmonary function and degree of spinal deformity, location of apical vertebrae and age among adolescent idiopathic scoliosis patients. Singapore Med J 57:33–38
- 68. Upadhyay S, Ho E, Gunawardene W, Leong J, Hsu L (1993) Changes in residual volume relative to vital capacity and total lung capacity after arthrodesis of the spine in patients who have adolescent idiopathic scoliosis. J Bone Joint Surg Am 75:46–52
- Pehrsson K, Bake B, Larsson S, Nachemson A (1991) Lung function in adult idiopathic scoliosis: a 20 year follow up. Thorax 46:474–478
- Muniyappanavar NS, Shivakumar J, Dixit PD, Shenoy JP, Teli SS, Chandrashekar A (2013) Impact of asymptomatic idiopathic scoliosis on pulmonary function. Natl J Physiol, Pharm Pharmacol 3:153–157

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.